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REAMBLE
his document was commissioned by the American College
f Cardiology Foundation (ACCF) Task Force on Clinical
xpert Consensus Documents (CECDs) to provide a per-
pective on the current state of complementary, alternative,
nd integrative medical therapies specifically as they relate
o cardiovascular diseases (CVDs). It is intended to inform practitioners, payers, and other interested parties of many
volving areas of clinical practice and/or technologies asso-
iated with this topic that are widely available or new to the
ractice community. Topics chosen for coverage by CECD
re so designated because the evidence base and experience
ith technology or clinical practice are not considered
ufficiently well developed to be evaluated by the formal
merican College of Cardiology/American Heart Associa-
ion (ACC/AHA) Practice Guidelines process. Often, the
opic is the subject of considerable ongoing investigation.
The Task Force on CECDs recognizes that considerable
ebate exists regarding the clinical utility of alternative
edicine practices. By their nature, alternative medicine
ractices differ widely in their scientific support. Despite
his varying evidence base, these practices are widely em-
loyed by patients, including those with CVD. Many
ractitioners are not familiar with many alternative medi-
ine techniques. Thus, the reader should view this CECD
s the best attempt of the ACCF to inform and guide
linical practice in an area where rigorous evidence is not yet
vailable or the evidence to date is not widely accepted.
here feasible, CECDs include indications or contraindi-
ations. The ACC/AHA Practice Guidelines Committee
ay subsequently address some topics covered by CECDs.
The Task Force on Clinical Expert Consensus Docu-
ents makes every effort to avoid any actual or potential
onflicts of interest that might arise as a result of an outside
elationship or personal interest of a member of the writing
anel. Specifically, all members of the writing panel are
sked to provide disclosure statements of all such relation-
hips that might be perceived as real or potential conflicts of
nterest. These statements are reviewed by the parent task
orce and updated as changes occur. Please see Appendix I
or the relationship with industry information pertinent to
his document.
Robert A. Vogel, MD, FACC
Chair, ACCF Task Force on Clinical Expert
Consensus Documents
. INTRODUCTION
rganization of Committee and Evidence Review
he Writing Committee consisted of acknowledged experts
n the field of complementary, alternative, and integrative
edicine. Both the academic and private sectors were
epresented. The document was reviewed by five official
eviewers nominated by the ACCF, representatives from
he American Association of Critical Care Nurses, AHA,
merican Nurses Association, Preventive Cardiovascular
urses Association, and the Society of Thoracic Surgeons,
s well as 20 content reviewers nominated by the Writing
ommittee. This document will be considered current until
he Task Force on CECDs revises or withdraws it from
ublication.
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lternative medical therapies encompass a broad spectrum
f practices and beliefs (1). From a historical standpoint,
hey may be defined as, “ . . . practices that are not accepted
s correct, proper, or appropriate or are not in conformity
ith the beliefs or standards of the dominant group of
edical practitioners in a society” (2). The Institute of
edicine (IOM) has recently reviewed complementary and
lternative medical practices in the U.S. from a general
iewpoint (3). This document will focus on cardiac aspects
f complementary medicine. From a functional standpoint,
lternative (also known as “complementary” or “integrative”)
herapies may be defined as interventions neither taught
idely in medical schools nor generally available in hospitals
4). Ernst et al. (5) contend that “complementary medical
echniques [complement] mainstream medicine by contrib-
ting to a common whole, by satisfying a demand not met
y orthodoxy or by diversifying the conceptual frameworks
f medicine.” The terminology currently in use to describe
hese practices remains controversial. Many commonly used
abels (e.g., “alternative,” “unconventional,” or “unproven”)
re judgmental and may inhibit the collaborative inquiry and
iscourse necessary to distinguish useful from useless tech-
iques (6). Complementary and alternative medicine (CAM)
s the language currently used by the National Institutes of
ealth (NIH) to describe this field of inquiry. The term
integrative medicine” has been used with increased fre-
uency. Several recently published studies and editorials
restle with the challenges of properly labeling and describ-
ng this field of inquiry (7–12). Herbs, vitamins, and
on-herbal dietary products, as well as therapies conducted
round issues such as spirituality, bioenergetics (i.e., acu-
uncture and energy fields), and mind/body, are all consid-
red to be forms of complementary, alternative, or integra-
ive medicine.
urpose of This CECD
he purpose of this CECD is to put the emerging area of
AM treatment and investigation into focus in order to
nable the physician to provide better patient care in a
eaningful and safe manner. The document will be con-
erned with the most recent advances and utilization of
AMs and therapies in a traditional cardiovascular practice.
In 2000, nearly 50% of all Americans sought the help of
n alternative health care practitioner. This represents over
00 million visits (13). Nearly $30 billion was spent in the
ear 2001 on CAM (13,14). Many CAM interventions,
ncluding numerous herbal supplements, have been em-
loyed in an attempt to treat CVD. Of prime importance is
utting CAM into perspective with its potential benefits
nd knowledge of important interactions with traditional
ardiovascular medicines. In response to an enormous in-
olvement in CAM, medical facilities have developed spe-
ialized CAM centers to investigate the potential benefits ind integrate those benefits into routine care and lifestyle
anagement.
The most complete and comprehensive findings to date
n Americans’ use of CAM were released on May 27, 2004,
y the National Center for Complementary and Alternative
edicine (NCCAM) and the National Center for Health
tatistics (NCHS, part of the Centers for Disease Control
nd Prevention) (15). The new data came from a detailed
urvey on CAM included for the first time in 2002 in the
ational Health Interview Survey (NHIS). The NHIS, a
urvey done annually by the NCHS, interviews people in
ens of thousands of American households about their
ealth- and illness-related experiences.
The findings are yielding (and will continue to yield,
hrough future analyses) a wealth of information on who
ses CAM, what they use, and why. In addition, researchers
an examine CAM use as it relates to many other factors
uch as age, race/ethnicity, place of residence, income,
ducational level, marital status, health problems, and the
ractice of certain behaviors that impact health (such as
moking cigarettes or drinking alcohol).
The survey showed that a large percentage of American
dults are using some form of CAM—36% (15). When
rayer specifically for health reasons is included in the
efinition of CAM, that figure rises to 62%. Dr. Stephen E.
traus, NCCAM Director, said, “The survey data will provide
ew and more detailed information about CAM use and the
haracteristics of people who use CAM. One benefit will be to
elp us target NCCAM’s research, training, and outreach
fforts, especially as we plan NCCAM’s second five years, 2005
hrough 2009.”
There is little doubt that CAM represents a revolution
ithin our health care delivery system. Nevertheless, our
raditional views of the medical establishment do not fully
upport CAM. There is a lack of significant instruction of
AM in medical schools, there is a paucity of CAM in most
ajor hospitals, and there is little solid research published in
eer-reviewed journals. Compensation by insurance compa-
ies for CAM is also an issue.
A recent report of the IOM entitled “Complementary
nd Alternative Medicine in the U.S.” (3) described and
haracterized CAM therapies used by the American public.
dditionally, the IOM sought to identify major scientific
olicy and practice issues related to CAM research and to
he translation of validated therapies into conventional
ractice. In short, the report recommended that the same
rinciples and standards of evidence of treatment effective-
ess apply to all treatments, whether currently labeled as
onventional medicine or CAM. Although randomized
ontrolled trials (RCTs) remain the “gold standard” of
vidence for treatment efficacy, the IOM noted that other
tudy designs can be used to provide information about the
ffectiveness when RCTs cannot be done or may not be
eneralizable to CAM practice. Other acceptable clinical
esearch designs included: preference RCTs (trials that
nclude both randomized and non-randomized treatment
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es; studies of bundles (combinations) of therapies; studies
hat specifically incorporate, measure, or account for placebo
r expectation effects; and attribute-treatment interaction
nalyses. Prioritization criteria were also proposed to assist
esearchers regarding which CAM therapies might warrant
urther investigation.
Integrating CAM into medicine must be guided by
ompassion, but enhanced by science, and made meaningful
hrough solid doctor-patient relationships. Most impor-
antly, CAM involves a commitment to the core mission of
aring for patients on a physical, mental, and spiritual level.
his document attempts to enable us to fulfill these objec-
ives. A glossary of terms is contained in Appendix II. For
dditional information on CAM, please refer to www.acc.
rg for Appendix III: Internet Sources for Complementary
edicine Information and Appendix IV: Review of the
iterature for Cardiovascular-Related Integrative Medicine.
I. NUTRITION AND SUPPLEMENTS
his section provides a discussion of general nutrition and
ietary supplements, including vitamins, minerals, and
erbs that are related to the prevention and reduction of risk
f CVD. Please see Appendix V at www.acc.org for a
ample dietary supplement intake form.
utrition
iet is a major determinant of cardiovascular health. Gen-
ral nutrition affects body weight, lipoproteins, blood pres-
ure, blood glucose, endothelial function, inflammation, and
oagulation. Dietary modification is an important compo-
ent of primary and secondary prevention of coronary heart
isease (CHD) and hypertension. The essentials of proper
utrition include appropriate caloric intake and consump-
ion of the essential macronutrients (carbohydrate, proteins,
nd fats) and micronutrients (vitamins, minerals). Specific
utrients can either accelerate or retard the development of
VD.
besity. Obesity contributes to CHD, diabetes, and hy-
ertension (16). Obesity (body mass index [BMI] greater
han 30 kg/m2) increased 50% in this country from 1991 to
998 (17). Almost one-third of Americans are now obese
nd another one-third are overweight (BMI 25 to 30
g/m2). The major cause of this recent increase in obesity is
150 to 200 kcal increase in our daily caloric intake, mainly
rom snacks (18). A decrease in physical activity associated
ith more television viewing has also contributed. A third
actor has been an increase in sugar consumption, which
ow averages 150 lbs per person per year (19). The latter
actor has also contributed to an increased prevalence of type
diabetes.
Weight loss is often an important part of the manage-
ent of CHD, diabetes, and hypertension (20). Excess
eight increases low-density lipoprotein (LDL) cholesterol,riglycerides, and markers of inflammation, such as e-reactive protein; and decreases high-density lipoprotein
HDL) cholesterol. Even modest weight reduction can
mprove these atherogenic markers (20). Weight loss only
ccurs when caloric intake is less than caloric expenditure.
he daily caloric requirement for sedentary and physically
ctive individuals, respectively, is about 12 and 15 kcal per lb
f ideal weight. A 3,500 kcal deficit results in approximately
lb of weight loss. On the average, a deficit or excess of 500
alories a day brings about weight loss or gain at the rate of
lb a week. Increasing physical activity also results in
eight loss. One mile walked or jogged is equivalent to
bout 100 calories burned. The most successful weight loss
rograms use calorie restriction, exercise, counseling, and
roup support.
Extremely low-carbohydrate or ketotic diets have become
opular for weight loss (21). Some randomized trials have
ound that obese individuals lose more weight on low-
arbohydrate diets than on low-fat diets, although the
ifference is not uniformly significant (22,23). The mecha-
isms by which extremely low-carbohydrate diets facilitate
eight loss include osmotic diuresis, glycogen and associ-
ted water depletion, anorexia due to ketosis, and exclusion
f foods. Although LDL cholesterol decreases during the
eight loss phase of low-carbohydrate dieting, levels return
o baseline in the long term. Two benefits of extremely
ow-carbohydrate diets are a decrease in triglycerides and an
ncrease in insulin sensitivity. The long-term cardiovascular
ffects of low-carbohydrate/high-fat diets are unknown, but
pidemiologic data suggest that they would increase athero-
clerosis (24).
Extremely low-fat diets have been used to treat estab-
ished coronary artery disease (CAD) (25). One small study
as demonstrated modest CAD regression (26). Extremely
ow-fat diets are difficult to apply widely. Low-fat diets are
onsistent with the general epidemiologic finding that
therosclerosis prevalence correlates with saturated fat in-
ake, and more specifically, with trans fat intake. However,
ow-fat diets can increase small LDL particles. These diets
lso do not recognize the cardiovascular benefits that can be
erived from omega-3 fatty acids. They also may increase
riglyceride levels and decrease insulin sensitivity.
acronutrients. Fatty acids can be generally characterized
nto saturated, trans, monounsaturated, and polyunsaturated
lasses depending on the number and configuration of
ouble bonds. Saturated and trans fatty acids increase serum
DL cholesterol and directly impair endothelial function
27,28). Trans fatty acids also decrease HDL cholesterol
29). Considerable data suggest an association between
ietary saturated and trans fats and CHD (24). Dietary
holesterol is also associated with CHD, but elevations in
erum cholesterol are individually variable with dietary
ntake. Monounsaturated fatty acids have neutral effects on
erum LDL and HDL cholesterol (30). Polyunsaturated
atty acids reduce HDL cholesterol, but their use in ran-
omized trials is associated with decreased cardiovascular
vents (27).
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ACCF Complementary Medicine Expert Consensus Document July 5, 2005:184–221Omega-3 fatty acids have three to six double bonds, the
rst one occurring between the third and fourth carbon
rom the methyl end. The omega-3 fatty acids have
riglyceride-reducing, membrane-stabilizing, antiplatelet,
nd anti-inflammatory properties (31). Omega-3 fatty acids
nclude alpha-linolenic, eicosapentaenoic, and decosahexae-
oic acids. The former is contained in plant oils, whereas
he latter two are contained in fish oils. Prospective ran-
omized trials have demonstrated that consuming plant and
sh omega-3 fatty acids reduces cardiovascular events,
udden death, and overall mortality (32).
Carbohydrates include monosaccharides, such as sugars,
ligosaccharides, and polysaccharides or starches. Complex
arbohydrates consist of starches and indigestible fiber.
iber adds bulk to food and slows carbohydrate digestion.
oluble fiber in the form of psyllium, guar gum, and oat
ran reduces serum LDL cholesterol (33). The blood
lucose raising property of a food per 50 g of carbohydrate
nd per portion is measured by its glycemic index and load,
espectively (34). High glycemic load foods such as cookies,
ice, and potatoes increase serum triglycerides, decrease
nsulin sensitivity, and probably facilitate obesity.
ietary recommendations. There are two types of dietary
uidelines. The first type recommends specific quantities of
acronutrients, such as less than 200 mg of cholesterol per
ay and less than 7% of calories as saturated fat, as in the
HA Step 2 diet (1). A second type recommends consump-
ion and exclusion of specific foods, often in combination.
n example is the recommendation to eat stanol/sterol ester
argarines, soy products, soluble fiber, and walnuts or
lmonds to lower LDL cholesterol (33,35,36). The latter
pecific food portfolio recommendation has been found to
ower LDL cholesterol more (29%) than an AHA Step 2
pproach (8%) (37). In general, diets containing unsaturated
ats, whole grains, fruits, vegetables, fish, and moderate
lcohol are optimal for preventing heart disease (38,39). In
ctober 2000, the AHA revised its dietary guidelines for
mericans (1). The new guidelines retain the principles of
he Step 1 and Step 2 diet but place emphasis on foods and
n overall eating pattern (see the following text) rather than
n percentages of food components such as fat.
The National Cholesterol Education Program (NCEP)
as issued new practice guidelines on the prevention and
anagement of high cholesterol in adults (40). The Third
dult Treatment Panel (ATPP III) of the NCEP further
odified its dietary recommendations to include a more
ntense and effective eating plan than previously advocated.
he new Therapeutic Lifestyle Changes (TLC) treatment
lan complements that of the AHA guidelines and recom-
ends less than 7% of calories from saturated fat and less
han 200 mg of dietary cholesterol daily. Total allowed fat
anges from 25% to 35% of total daily calories provided that
aturated fats and trans fatty acids are kept low. The ATP
II encourages the use of foods that contain plant stanols
nd sterols or are rich in soluble fiber, to achieve greater
DL cholesterol-lowering power. bediterranean diet. The prevalence of CVD is consider-
bly less in Mediterranean and Pacific Rim countries than in
he U.S. at equivalent cholesterol levels (41). Common to
uch societies is a diet high in fruits, vegetables, beans,
hole-grain carbohydrates, nuts, fish, and monounsaturated
nd polyunsaturated oils. Dairy products are consumed in
ow-to-moderate amounts and little red meat is eaten.
lcohol is consumed in moderation. The Lyon Diet Heart
tudy (42,43) tested the effectiveness of a Mediterranean-
ype diet, modified by substitution of an alpha-linolenic
cid-enriched canola oil margarine for olive oil, on cardio-
ascular risk after a first myocardial infarction. After an
verage follow-up of 46 months, subjects following the
odified Mediterranean-style diet had 72% fewer cardio-
ascular events and 60% lower all-cause mortality. Findings
rom the Lyon Diet Study have been reproduced recently
sing an Indo-Mediterranean diet in subjects with CHD
44). The intervention diet recommending increased con-
umption of fruits, vegetables, nuts, whole grains, and
ustard and soybean oils reduced cardiovascular events by
5% and sudden cardiac death by 66%. Additionally, rec-
mmendations to increase fruit, vegetables, and low-fat
airy product consumption has been found to lower blood
ressure in the Dietary Approaches to Stop Hypertension
DASH) study (45).
ummary of general nutritional recommendations.
Achieve and maintain ideal body weight by limiting
foods high in calories and low in nutrient density,
including those high in sugar, such as soft drinks and
candy.
Eat a variety of fruits, vegetables, legumes, nuts, soy
products, low-fat dairy products, and whole grain breads,
cereals, and pastas.
Eat baked or broiled fish at least twice per week.
Choose oils and margarines low in saturated and trans fat
and high in omega-3 fat, such as canola, soybean, walnut,
and flaxseed oils, including those fortified with stanols
and sterols.
Avoid foods high in saturated and trans fats, such as red
meat, whole milk products, and pastries.
If you drink alcohol, limit consumption to no more than
2 drinks per day for a man or 1 drink per day for a
woman.
Eat less than 6 g of salt or less than 2,400 mg of sodium
per day.
Be physically active. Get 30 min of exercise daily.
ioactive Components in Foods
ood components recommended for lowering the risk of
VD include plant sterols, soluble fiber, omega-3 fatty
cids, nuts, and soy. Additional foods, such as garlic and
eas, and moderate alcohol use will be discussed.
mega-3 fatty acids. Individual fatty acids have remark-
bly diverse effects on coronary risk factors and vascular
iology (41–45). Omega-3 and -6 fatty acids are essential
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July 5, 2005:184–221 ACCF Complementary Medicine Expert Consensus Documentutrients. Dietary fatty acids affect eicosanoid products (e.g.,
hromboxanes, leukotrienes, prostaglandins) responsible for
asoregulation, inflammation, and coagulation. Omega-3
atty acids may also affect CHD outcomes by decreasing
riglyceride levels, ventricular arrhythmias, decreasing fi-
rinogen levels and platelet counts, modestly reducing blood
ressures, and decreasing cell proliferation. Improvements
n arterial compliance and endothelial function have also
een documented with fish oil, a major supply of dietary
mega-3 fatty acids. There are changes in autonomic tone
as observed by improvement in heart rate variability mea-
ures) and in mood (depression) (46).
Epidemiologic studies (47–51) have generally shown an
nverse correlation between consumption of fish or other
ources of dietary omega-3 fatty acids and cardiovascular
vents. Conversely, other epidemiologic studies (52–55)
ave failed to document the benefits of fish consumption.
ood plant sources of the 18 carbon omega-3 fatty acid,
lpha-linolenic acid, include flaxseed, canola, pumpkin seed,
alnut, and soybean oil.
Omega-3 fatty acids have been tested in several secondary
revention trials. Four prospective, controlled intervention
rials with either oily fish (56) or omega-3 fatty acid capsules
42,57,58) have demonstrated reduced cardiovascular
vents. However, in the DART trial, fish consumption
educed overall mortality early after myocardial infarction
MI) (56), but was associated with higher risk over the
ubsequent three years of the study (53). The GISSI-
revenzione study is the largest of the controlled trials
nvestigating omega-3 fatty acid supplements (1 g per day)
nd CHD risk. In this trial, total mortality was reduced by
0% and sudden death by 45% in an intention-to-treat
nalysis. Mortality was reduced through a decreased inci-
ence in sudden death.
Studies published to date are mixed regarding a role for
ietary omega-3 fatty acids in the prevention of restenosis
fter percutaneous coronary angioplasty (59–62). They have
ot been found to reduce coronary atherosclerosis progres-
ion to a significant extent (58,63). One study demonstrated
hat occlusion of aortocoronary venous bypass grafts was
educed after one year by daily ingestion of 4 g of fish-oil
oncentrate (64).
tanol/sterol esters. Plant sterols or phytosterols have
een known to have a cholesterol-lowering effect since the
950s. The esterification of plant stanols renders them
oluble in dietary fat, an effective vehicle for delivering plant
tanols and sterols to the site of cholesterol absorption in the
mall intestine. Commercially available margarines that pro-
ide 3.4 to 5.1 g a day of plant stanol esters can significantly
educe serum total and LDL cholesterol levels without
ffecting HDL cholesterol or triglycerides (65–67). A de-
rease in LDL cholesterol levels of 9% to 20% can be
chieved with consumption of approximately 2 g per day of
lant sterol esters (36). In a randomized, eight-week
lacebo-controlled trial in 167 subjects, using plant stanol
sters incorporated into an oil-based margarine, there was a pignificant reduction in serum total (12%) and LDL (17%)
holesterol levels in individuals taking a stable dose of a
tatin drug (68). No trials have studied the effects of
tanol/sterol esters on cardiovascular risk. Stanol and sterol
sters should be avoided by the rare individual with familiar
itosterolemia.
arlic (Allium sativum). Garlic is an herb that has been
sed for thousands of years as a food and spice. Garlic
otentially affects plasma lipids, fibrinolytic activity, platelet
ggregation, blood pressure, and blood glucose (69). Various
ormulations/preparations of garlic and different study de-
igns have led to contradictory results. The Agency for
ealthcare Research and Quality (AHRQ) (70) noted on
eview of 36 randomized trials modest, short-term effects of
arlic supplementation on lipid and antithrombotic factors.
arious garlic preparations led to small but significant
eductions in total cholesterol at one month and at three
onths (range of average pooled reductions 11.6 to 24.3
g/dl). Eight six-month controlled trials showed no signif-
cant reductions. Effects on clinical outcomes are not estab-
ished, and effects on glucose and blood pressure are none to
inimal. A similar meta-analysis conducted by Stevinson et
l. (71) that included 13 randomized, placebo-controlled
rials concluded that the use of garlic for hypercholesterol-
mia was of questionable value. Superko and Krauss (72)
emonstrated in a randomized, placebo controlled trial in
ypercholesterolemic subjects that garlic has no effect on
ajor plasma lipoproteins and that it does not impact HDL
ubclasses, Lp(a), apolipoprotein B, postprandial triglycer-
des, or LDL subclass distribution.
oy. Soy-based foods have cholesterol-lowering, estro-
enic, and antioxidant properties. The mechanism underly-
ng the cholesterol-lowering effect of soy is likely multifac-
orial. Soy-based foods reduce lipid oxidation, promote
ncreased vascular reactivity, and improve arterial compli-
nce (73). Favorable effects of soy phytoestrogens on lipid
rofiles, vascular reactivity, thrombosis, and cellular prolif-
ration have been reported (74). Dietary intake of foods
ontaining phytoestrogens is associated with a favorable
ardiovascular risk profile as was demonstrated in 939
ostmenopausal women participating in the Framingham
ff-Spring Study (75). The consumption of soy protein can
mprove lipid profiles in hypercholesterolemic individuals
bove a background NCEP Step I diet. Soy decreases LDL
holesterol more in hypercholesterolemic individuals. Soy
upplementation may also increase the levels of HDL
holesterol regardless of whether an individual is hypercho-
esterolemic or not. A meta-analysis of 38 trials of soy
rotein demonstrated reductions in total cholesterol of
.3%, LDL cholesterol of 12.9%, and triglyceride levels of
0.5%, accompanied by an increase of 2.5% in HDL
holesterol (76). However, more recent studies in post-
enopausal women fail to show improvements in plasma
ipids (77). A recent placebo-controlled study in 108 men
nd 105 postmenopausal women randomized to either soy
rotein isolate or casein placebo for three months demon-
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ith no improvement in indices of arterial function (78).
xtracts of soy isoflavones given to human subjects do not
esult in cardiovascular benefits except for improvements in
ystemic arterial compliance (79).
The clinical benefit of isoflavones is unclear. In light of
he recent findings about estrogen from the Women’s
ealth Initiative, the U.S. Preventive Services Task Force
as stated that the evidence is inconclusive to determine
hether phytoestrogens, such as soy isoflavones, are effec-
ive for reducing the risk of CVD (80).
oluble fiber. Soluble or viscous fibers, such as oat bran,
syllium, guar, and pectin, are thought to reduce heart disease
y lowering total and LDL cholesterol levels without affecting
erum triglycerides. Conversely, insoluble wheat fiber and
ellulose have no cholesterol-lowering effects unless used in the
iet to replace foods supplying saturated fats or cholesterol
81). Increasing dietary fiber has been recommended as a safe
nd practical approach to cholesterol reduction. Large epide-
iologic studies (82–84) have demonstrated a reduced risk for
Is and death from CHD in both men and women who
onsume higher amounts of dietary fiber. These studies pro-
ide strong support linking dietary fiber intake to protection
rom CHD. These data are supported by numerous ecological,
ohort, case-comparison, population-based, and, most re-
ently, clinical trials demonstrating an inverse relationship
etween dietary fiber consumption and atherosclerotic CVD
85).
The hypocholesterolemic effects of psyllium (86), guar
um (87), and oat bran (88) are documented by meta-
nalyses (89). A meta-analysis of 67 controlled trials study-
ng the cholesterol lowering effect of four types of soluble
ber (oat, psyllium, pectin, and guar gum) reported small but
ignificant reductions in total cholesterol (1.7 mg/dl per g
oluble fiber) and LDL (cholesterol (1.9 mg/dl per g soluble
ber) (81). Hypercholesterolemic subjects with initially
igher cholesterol levels experienced the most significant
eductions. Triglycerides and HDL cholesterol were not
ignificantly influenced by soluble fiber. The magnitude of
ipid lowering was found to be similar for oat, psyllium, or
ectin-based fibers.
Because of the favorable effect of soluble fiber on LDL
holesterol levels, the ATP III panel recommends that the
iet be enriched by foods that provide a total of at least 5 to
0 g of soluble fiber daily (90). Dietary fiber also reduces
lood pressure, obesity, insulin resistance, and clotting
actors—all independent risk factors for CHD (85).
uts. The few studies that have looked at the consumption
f whole nuts in relation to CHD have reported a consistent
nd substantial protective effect. Three of the largest nutri-
ional epidemiologic prospective studies evaluating multiple
opulation groups, ages, races, and gender have found a
onsistent inverse relationship between nut consumption
nd coronary risk (91–93).
The improvement in serum lipids associated with the
onsumption of nuts does not explain the magnitude of the (HD risk reduction of approximately 40% to 50% found in
he epidemiologic studies. Nuts, especially walnuts and
lmonds, are high in arginine, magnesium, folate, plant
terols, and soluble fiber. Some nuts contain high levels of
mega-3 essential fatty acids (e.g., walnuts), and they are an
xcellent source of vitamin E. In a prospective study of
6,016 women between the ages of 34 to 59 years, without
reviously diagnosed CHD, eating 5 oz of nuts per week
as associated with a relative risk (RR) of 0.66 (95%
onfidence interval [CI] 0.47 to 0.93, p for trend  0.005)
f coronary events adjusted for risk factors and independent
f fiber, fruit, and vegetable supplements (92). Recent
rospective data from the Physicians’ Health Study demon-
trated consumption of nuts two or more times a week
ignificantly reduced the risk of sudden cardiac death (RR)
f 0.53 (95% CI 0.30 to 092, p for trend  0.01) and a RR
f 0.70 (95% CI 0.50 to 0.98, p for trend  0.06) for total
HD deaths compared with men who rarely or never
onsumed nuts (93). The association between nut consump-
ion and sudden cardiac death became stronger after adjust-
ent for lifestyle, cardiac risk factors, and diet. Like some
uts, canola oil and flaxseed oil are the richest known source
f alpha-linolenic acid, an omega-3 fatty acid.
ea. Tea drinking appears to be protective against CHD in
number of epidemiologic studies (94–97). In the older
ohort of the Rotterdam Study, an inverse association was
emonstrated between tea drinking and advanced aortic
therosclerosis (98). Data from a more recent follow-up of
he Rotterdam Study highlighted a strong inverse relation
etween tea intake (greater than 375 ml/day) and MI with
he relation being stronger in women than in men. The
nverse association with tea drinking was stronger for fatal
vents than for nonfatal events. For flavonoid (quercetin 
aempferol  myricetin) intake, a strong association with
I was observed only in women (99). Results are incon-
lusive for clinical and case control studies. However, a
ecent prospective cohort study of 1,900 patients hospital-
zed with an acute MI followed for 3.8 years found a
ignificantly reduced hazard ratio for subsequent total and
ardiovascular mortality of 0.56 (95% CI 0.37 to 0.84) for
eavy tea drinkers (more than 14 cups/week) compared to
on-tea drinkers (100). A recent clinical study has shown
hat consumption of black tea improves brachial artery
ow-mediated dilation in patients with CAD (101). De-
pite the favorable epidemiology and mechanistic investiga-
ions, no studies have prospectively documented a reduction
n cardiovascular risk with tea drinking.
lcohol. Epidemiologic studies have shown that the inci-
ence of MI, angina pectoris, and coronary-related deaths
re inversely related to moderate alcohol intake, as defined
y 1 to 3 drinks daily. Although many mechanisms for this
ffect have been suggested, the best documented effect is an
ncrease in HDL cholesterol by alcohol (102). Recent
tudies have shown that moderate drinkers are less likely to
uffer ischemic stroke (103,104), peripheral vascular disease
105), and death following an acute MI (106). Cooper et al.
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ricular systolic dysfunction had fewer adverse outcomes. In
he Framingham Heart Study, Walsh et al. (108) found that
he incidence of congestive heart failure was lower in
ubjects who consumed moderate amounts of alcohol.
bramson et al. (109) were able to demonstrate that
ubjects who consumed moderate levels of alcohol had a
ignificantly lower risk of developing heart failure.
Moderate consumption of alcohol-containing beverages
oes not appear to result in significant morbidity; however,
eavy alcohol consumption can result in cardiomyopathy,
ypertension, hemorrhagic stroke, cardiac arrhythmia, and
udden death. Alcohol ingestion poses such a number of
ealth hazards with irresponsible consumption that the
HA recommends that physicians and patients discuss the
dverse and potentially beneficial aspects of moderate drink-
ng (39).
verview of dietary supplements. The Dietary Supple-
ent Health and Education Act (DSHEA) of 1994 defined
ietary supplements as a product (other than tobacco)
ntended to supplement the diet for such ingredients as
itamins, minerals, herbs, or other botanicals, amino acids,
nd substances such as enzymes, organ tissues, glandulars,
nd metabolites. Whatever their form, the DSHEA places
ietary supplements in a special category under the general
mbrella of “foods,” not drugs, and requires that every
upplement be labeled a dietary supplement. The establish-
ent of dietary supplements as foods limited the Food and
rug Administration (FDA)’s premarketing regulatory au-
hority and placed the FDA in a reactive, postmarketing
ole. Thus, for the FDA to remove a supplement from the
arket it most prove that the supplement presents a
ignificant or unreasonable risk of injury or illness when
sed as recommended on the label. Recently, the IOM has
rged that the U.S. Congress and federal agencies, in
onjunction with industry, research scientists, consumers,
nd other stakeholders, amend DSHEA and the current
egulatory practices for dietary supplements in an effort to
mprove product consistency and reliability (IOM, 2005).
ust prior to the release of the IOM report on Complemen-
ary and Alternative Medicine in the U.S., the FDA
nnounced three major regulatory initiatives designed to
urther implement DSHEA (http://www.cfsan.fda.gov/
lrd/fr04119a.html, docket no. 2004N-0458). These initi-
tives serve to inform the dietary supplement industry on a
egulatory strategy involving the monitoring and evaluation
f product and ingredient safety, assurance of product
uality via good manufacturing practice (CGMP regula-
ions), and monitoring and evaluation of product labeling.
t the same time these new initiatives will give consumers
higher level of assurance about the safety of dietary
upplement products and the reliability of their labeling.
itamin and Mineral Supplements
ntioxidant vitamins. Antioxidant therapies are poten-
ially useful in preventing both atherosclerosis and its iomplications by retarding LDL oxidation and by inhibiting
he proliferation of smooth muscle cells, platelet adhesion
nd aggregations, the expression and function of adhesion
olecules, and the synthesis of leukotrienes (110). Antioxi-
ants may improve endothelial function, reduce ischemia,
nd stabilize atherosclerotic plaques to prevent plaque
upture (110).
ITAMIN E. Primary Prevention Trials. A potential benefit
f vitamin E in CHD is suggested by two large prospective
pidemiologic trials, which found lower event rates in
ubjects who took at least 100 units of vitamin E per day
111,112). However, 50 mg of vitamin E in the Alpha-
ocopherol, Beta-Carotene (ATBC) cancer prevention trial
f male smokers did not decrease nonfatal MIs, and
ncreased hemorrhagic stroke (113,114). Vitamin E use was
ot associated with decreased stroke in the Health Profes-
ionals Follow-Up Study (115), the Nurses Health Study
112), and the Iowa Women’s Health Study (116). Most
ecently, the Collaborative Group of the Primary Prevention
roject (PPP) found no decrease in cardiovascular events in
,495 subjects with one or more risk factors after 3.6 years
f synthetic vitamin E (300 units) therapy compared to
one (117). These data have been confirmed by a recent
ooled analysis of nine cohort studies (Pooling Project of
ohort Studies on Diet and Coronary Disease) in 293,172
ubjects free of CHD. A lower CHD risk at higher intake
f dietary vitamin E was present when adjusted for age and
nergy intake. However, supplemental vitamin E intake was
ound not to be significantly related to a reduced risk of
HD (118).
Secondary Prevention Trials. Only one of several con-
rolled trials of vitamin E has shown a reduction in some
spect of cardiovascular risk. In the Cambridge Heart
ntioxidant Study (CHAOS) (119) vitamin E reduced the
isk of nonfatal MI, but not of fatal MI. The Heart
utcomes Prevention Evaluation (HOPE) study found no
ffect of vitamin E for several of primary and secondary
VD end points, including disease progression monitored
y carotid ultrasound (120). The GISSI-Prevenzione trial
42) failed to show benefit from vitamin E supplementation
n CHD or stroke in almost 8,000 patients. The Vitamin E
therosclerosis Prevention Study (VEAPS) provided addi-
ional evidence that vitamin E supplementation (400 units)
id not reduce the progression of atherosclerosis as evalu-
ted by change in intimal medial thickness (121). A meta-
nalysis of seven randomized trials of vitamin E (50 units to
00 units) in 81,788 patients confirmed that vitamin E did
ot reduce mortality, decrease cardiovascular death, or
erebrovascular accident (122). A more recent and larger
135,967 participants in 19 clinical trials) meta-analysis that
onsidered the dose dependent effects of vitamin E supple-
entation noted that at high dosage (400 units/day or
ore) a pooled risk difference of 34 per 10,000 persons
95% CI 5 to 63 per 10,000 persons, p  0.022). However,
t is unclear whether the investigators isolated the effects of
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vidence for an elevated mortality risk came from two trials
hat administered vitamin E together with beta-carotene. It
s uncertain whether an increased risk for death from
igh-dose vitamin E based on this most recent analysis of
CTs exists (123).
ITAMIN C. Primary Prevention. When examined individu-
lly, most observational and prospective cohort studies do
ot demonstrate a relationship between vitamin C intake
nd CVD (124,125) and there have been no RCTs specif-
cally examining the effects of vitamin C supplementation
n cardiovascular end points (115,126). In the Iowa Wom-
n’s Health Study, women in the top quintile of vitamin C
ntake versus the lowest quintile had a nonsignificant
ncreased risk for CHD mortality and a borderline signifi-
ant trend toward increased stroke (127). Long-term use of
itamin C in a large prospective investigation was not
ssociated with a reduced risk of stroke, as well (115).
owever, a more recent analysis from the Nurses’ Health
tudy indicates that women in the highest quintile of intake
or vitamin C (greater than 360 mg per day from diet and
upplements) compared with the lowest quintile (less than
r equal to 93 mg per day), had a 27% lower risk for CHD,
nd women taking supplemental vitamin C had a 28% lower
isk of nonfatal MI and fatal CHD compared with women
ho took no vitamin C (128). In the recent pooled analysis
rom the Pooling Project of Cohort Studies on Diet and
oronary Disease (118), those subjects with higher supple-
ental vitamin C intake (greater than 700 mg/day) had a
5% reduced risk of CHD. Nevertheless, the current con-
ensus does not find a value for supplemental vitamin C in
reventing heart disease (129).
ETA-CAROTENE. Trials of beta-carotene have demon-
trated no cardiovascular benefit, and one demonstrated an
dverse clinical outcome. An increased incidence of lung
ancer and CVD mortality were observed in the ATBC
ancer prevention study (130). Beta-carotene supplementa-
ion was also associated with a slight increase in the
requency of angina pectoris (131). A meta-analysis of eight
rials evaluating beta-carotene in 138,113 patients revealed a
mall but significant increase in all-cause mortality and
ardiovascular death (128). Thus, beta-carotene supplemen-
ation is discouraged (1).
Combination Vitamin Trials. The Heart Protection Study
HPS) randomized 20,536 subjects at high risk for CHD to
0 mg simvastatin daily or placebo and vitamin E (600 mg),
itamin C (250 mg), and beta-carotene (20 mg) or placebo.
fter 5.5 years of study, no benefit from combination
itamin therapy was evident (132). A small RCT, the HDL
holesterol Atherosclerosis Treatment Study (HATS),
ound that vitamin C (1 g), vitamin E (800 units), beta-
arotene (50 mg), and selenium (100 mcg) reduced the
enefit of simvastatin plus niacin therapy on CAD progres-
ion and cardiovascular events (133) suggesting a potential
rug/supplement interaction affecting the efficacy of statin aherapies. Lack of benefit for combination vitamin E (400
nits) and vitamin C (500 mg) was also documented in 423
ostmenopausal women with CAD participating in the
omen’s Angiographic Vitamin and Estrogen (WAVE)
rial (134).
In contrast to the aforementioned negative trials, the
ntioxidant Supplementation in Atherosclerosis Prevention
ASAP) study of 440 hypercholesterolemic patients ran-
omized to vitamins E and C, reported that combination
herapy decreased the rate of atherosclerosis progression
especially in men) over a six-year period as measured by
arotid artery intima-media thickness. This study selected
ubjects with high oxidative stress and maximized absorp-
ion of the antioxidants by giving them with meals (135).
In summary, aside from the recent pooled analysis of
itamin C cohort studies, the consensus of antioxidant
itamin study results do not support a cardiovascular benefit
elated to the use of vitamins E and C and beta-carotene
129).
OLIC ACID, VITAMIN B6, AND VITAMIN B12. Elevated homo-
ysteine levels are associated with increased risk of coronary
rtery and vascular disease. The mechanisms by which
levated homocysteine impairs vascular function are not
ompletely understood, but may involve the stimulation of
ascular smooth muscle cell growth and collagen synthesis,
xidative-endothelial injury and dysfunction, lipid peroxi-
ation and platelet activation, and hypercoagulability (136).
ntakes of folate, vitamins B6, and B12 are inversely related
o homocysteine levels as all three vitamins are directly
nvolved in the metabolism of homocysteine. Beginning in
996 and mandatory in 1998, the FDA issued a regulation
equiring all enriched grain products be fortified with folic
cid (140 mcg/100 g serving portion), primarily for the
eduction of congenital neural tube defects. The fortification
f enriched grain product with folic acid has been associated
ith an improvement in the folate status of middle-aged
nd older adults (137). In the Framingham Offspring Study
ohort, mean homocysteine levels decreased from 10.1 to
.4 mol/l with the introduction of fortified products (138).
Initial retrospective case-control studies (139–141) and
rospective studies (142–147) suggested an inverse relation-
hip between homocysteine and CVD. A recent meta-
nalysis, combining 30 prospective and retrospective studies,
oncluded that elevated homocysteine is less strongly related
o ischemic heart disease and stroke risk in healthy popu-
ations than has been suggested (148). A meta-analysis of 14
rospective cohort studies, using the inclusion criterion of
ime to first cardiac or cerebrovascular event, found that
levated homocysteine levels moderately increased the risk
f a first cardiovascular event, regardless of age and duration
f follow-up (149).
In secondary prevention studies, two nonrandomized
rials in patients with vascular disease found an inverse
elationship between the intake of folic acid and vitamin B6
nd vascular events (150). One study conducted in open-
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July 5, 2005:184–221 ACCF Complementary Medicine Expert Consensus Documentabel fashion in 593 patients with coronary artery disease on
tatin therapy showed no benefit of folic acid in reducing
ardiovascular events despite an 18% lowering in homocys-
eine levels (151–153).
Most recently, a trial of folic acid (1 mg), vitamin B12
400 units), and pyridoxine (B6) (10 mg) found a signifi-
antly reduced homocysteine levels, rate of restenosis, and
eed for revascularization in a group of 553 CAD patients
t one year of follow-up (151,152). A similar RCT of 626
atients treated with B-vitamin therapy following coronary
tenting procedures, however, found increased rates of
estenosis, particularly in patients receiving bare-metal
tents and major adverse cardiac events in the vitamin
reated group after one year of follow-up. The rate of
estenosis in the homocysteine-lowering group was 35%
ompared with 27% in the group receiving placebo (154).
lthough striking differences exist between the study pop-
lations, it raises the potential of possible harm from use of
igh-dose B-vitamins. Strong evidence for a benefit for B
itamins in CVD is pending; there remain a number of
ngoing trials, including WACS, SEARCH, PACIFIC,
ORVIT, and CHAOS-2 (155).
inerals. MAGNESIUM. Magnesium metabolism is in-
olved in insulin sensitivity and blood pressure regulation,
nd magnesium deficiency is common in both diabetes and
ypertension. The links among magnesium, diabetes, and
ypertension suggest the possibility that magnesium can
ffect CVD (156,157). Magnesium depletion is associated
ith electrocardiographic changes, arrhythmias, and in-
reased sensitivity to cardiac glycosides (158). Epidemio-
ogic studies have suggested that ingesting hard water that
ontains magnesium, consuming a diet higher in magne-
ium, or using magnesium supplements decreases CVD
159). The Honolulu Heart Program found a 1.7- to
.1-fold excess risk of CHD among those subjects in the
owest versus highest quintile of magnesium intake after 15
ears of follow-up (160). Similarly, epidemiologic evidence
uggests that magnesium may play a role in regulating blood
ressure (161–165). A recent meta-analysis of 20 random-
zed studies including both normotensive and hypertensive
ubjects detected a dose-dependent blood pressure reduc-
ion with magnesium supplementation (166). The DASH
ntervention study demonstrated that a diet of fruits and
egetables, which increased magnesium intake from an
verage of 176 to 423 mg per day, significantly lowered
lood pressure in adults who were not classified as hyper-
ensive (167). However, studies in hypertensive patients
ave led to conflicting results. Ascherio et al. (168) found an
nverse correlation between the intake of magnesium and
he risk of stroke.
Magnesium intake has been found to be inversely asso-
iated with carotid artery thickness in women but not in
en (163). Oral magnesium therapy (365 mg twice daily for
months) in 187 patients with CAD demonstrated a 14%
mprovement in exercise duration combined with a decrease
n exercise-induced chest pain compared to no change in the mlacebo group (169). In patients with congestive heart
ailure (CHF), a population at high risk for magnesium
eficiency, oral magnesium replacement decreases the fre-
uency of ventricular arrhythmias (170).
Dietary intakes of magnesium are suboptimal in the U.S.
s evidenced by recent NHANES survey intake data (171).
iets rich in magnesium and magnesium supplementation
ay be helpful in preventing CVD, especially hypertension.
ther bioactive supplements. COENZYME Q10. Coenzyme
10 (CoQ10) is involved in oxidative phosphorylation and
he generation of adenosine triphosphate (ATP). The
oQ10 acts as a free radical scavenger and membrane
tabilizer. There have been over 40 controlled trials of the
linical effect of CoQ10 on CVD, a majority of which show
enefit in subjective (quality of life, decrease in hospitaliza-
ions) and objective (increased left ventricular ejection frac-
ion, stroke index) parameters. A recent review (172) and
eta-analysis (173) have shown benefit of CoQ10 as
djunctive treatment in patients with CHF. The largest trial
o date was a one-year, placebo-controlled study of CoQ10
n 651 New York Heart Association (NYHA) functional
lass III or IV CHF patients (174). These investigators
ound a significant decrease (38% to 61%) in the number of
ospitalizations, incidences of pulmonary edema, and epi-
odes of cardiac asthma. No differences in death rates were
ocumented. However, two of the most recent placebo-
ontrolled trials found that the addition of 100 to 200
g/day of oral CoQ10 to conventional medical therapy did
ot result in significant improvement in left ventricular
jection fraction, peak oxygen consumption, exercise per-
ormance, or quality of life in patients with advanced heart
ailure (175,176).
A mortality benefit for CoQ10 has not been established
n contrast to angiotensin-converting enzyme inhibitors,
eta-blockers, and aldosterone antagonists. Case reports
ssociate CoQ10 therapy with decreased internation nor-
alized ratio (INR) in patients taking warfarin (177);
owever, CoQ10 had no effect on the INR in patients on
arfarin in a randomized, double-blind, placebo-controlled,
rossover trial (178). Caution is advised if patients are taking
oQ10 and warfarin. The HMG-CoA reductase inhibitors
ay inhibit the natural synthesis of CoQ10, and reduced
evels of CoQ10 have been documented in small controlled
linical trials in patients on statin therapies (179). Reduced
evels of CoQ10 may place the patient at increased risk for
yopathy (180–183); however, studies of CoQ10 for de-
reasing myalgias and myositis are not definitive. One
nique formulation of CoQ10 has received FDA Orphan
rug status for treating mitochondrial disorders. The value
f CoQ10 in CVD and with statin use has not been clearly
stablished.
-CARNITINE. In 1986, the FDA-approved L-carnitine for
se in primary carnitine deficiency, which manifests as a
isruption in the transport of free fatty acids across the
itochondrial membrane for energy production. In myo-
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ACCF Complementary Medicine Expert Consensus Document July 5, 2005:184–221athic carnitine deficiency, muscle weakness is paramount
184). Convincing evidence is lacking for the use of carni-
ine in patients without carnitine deficiency undergoing
ardiac surgery, in patients with angina pectoris, acute
yocardial infarction, shock, and peripheral vascular disease
185). Urinary carnitine excretion is known to be increased
n patients with heart failure (186). Several clinical RCTs
ave evaluated the addition of L-carnitine to standard
edial therapy for heart failure with mixed results (187–
89). Significant improvements in maximum exercise times
nd ejection fractions were reported by Mancini et al. (190)
n 60 patients with NYHA functional class II or III CHF
ho were randomized either to propionyl-L-carnitine (50
g t.i.d.) or placebo for 180 days. Two other small trials
eported similar results, and one trial showed improvement
t a higher dose. In a double-blind randomized trial in 155
atients with claudication, a significant improvement in
xercise treadmill performance (54% increased walking
ime) and functional status was achieved with oral
ropionyl-L-carnitine 2 g/day for 6 months (191). Differ-
nces in effect may be due to the dose and formulation of
arnitine. In contrast, the investigators of the Study on
ropionyl-L-Carnitine in Chronic Heart Failure did not
how improved exercise tolerance on L-carnitine supple-
entation (187).
At present, it is unclear whether L-carnitine provides any
enefit beyond well-established therapies. A more definitive
nswer will come from the Carnitine Ecocardiografia Digi-
alizzata Infarto Miocardico (CEDIM-2) trial, which will
ssess the efficacy of L-carnitine in approximately 4,000
atients with acute MI over six months (192). Supplements
ontaining D- or DL-carnitine, often present in over the
ounter preparations and dietary supplements, should not be
ubstituted for L-carnitine. Carnitine frequently causes
ausea, pyrosis, dyspepsia, and diarrhea. Concomitant use
f carnitine with warfarin may potentiate warfarin’s antico-
gulant effects.
-ARGININE. L-arginine is the precursor of nitric oxide
NO) and has been shown to improve coronary and brachial
rtery endothelial function and reduce monocyte/
ndothelial cell adhesion (193–195). In patients with recur-
ent chest pain, improvements in coronary blood flow in
esponse to acetylcholine have also been documented. In
ypercholesterolemic subjects, dietary supplementation with
-arginine over two weeks has been shown to normalize the
dhesiveness of mononuclear cells (196) and reduce platelet
ggregability (197). However, in a study in 30 patients with
AD, supplemental L-arginine did not affect measures of
O bioactivity and NO-regulated markers of inflammation
198).
There are a few documented reports of adverse effects
rom oral use of L-arginine. Several patients with hepatic
mpairment and a recent history of spironolactone use were
eported to develop severe hyperkalemia upon initiation or
rginine hydrochloride for management of metabolic alka- wosis (199). Oral L-arginine appears to have potential
enefit in CHD, but hard evidence for its value is currently
ot available.
erbal Preparations
n the U.S. today, herbs may be marketed as dietary
upplements providing their intended use is not to diagnose,
reat, cure, or prevent disease. A number of approved drug
ubstances have their origin in plants, such as digoxin,
tropine, reserpine, and amiodarone. However, only a few
erbal products available in the U.S. have been tested for
ardiovascular purposes: hawthorn (heart failure and coro-
ary insufficiency), garlic (atherosclerosis), ginkgo (arterial
cclusive disease), and horse chestnut (chronic venous
nsufficiency) (200). Few U.S. products benefit from rigor-
us characterization and standardization necessary for clin-
cal study.
awthorn (Crataegus). Hawthorn has positive inotropic
ffects and is a peripheral vasodilator. It increases myocar-
ial perfusion and stroke volume and reduces afterload.
ntiarrhythmic effects have been reported in an ischemia-
eperfusion model. Orally, hawthorn leaf extract has been
sed for CHF, cor pulmonale, ischemic heart disease,
rrhythmias, blood pressure reduction, atherosclerosis, and
erebral insufficiency (200). Preparations made from flowers
ith leaves are sold as a prescription medication in parts of
urope and Asia. For example, in Germany, hawthorn can
e prescribed for “mild cardiac insufficiency.”
Several double-blind clinical studies of patients diagnosed
ith heart failure have shown objective improvement in
ardiac performance using bicycle ergometry (201,202) or
piroergometry. In one study, hawthorn was found to be as
ffective as captopril in improving exercise tolerance. Based
n ergometric performance parameters, the minimum ef-
ective daily dose of hawthorn extract is 300 mg. In most
rials, the maximum benefit was seen after 6 to 8 weeks of
herapy. Weikl et al. (203) demonstrated an improvement in
xercise performance in 136 stage II CHF subjects receiving
60 mg hawthorn special extract WS 1442 (leaves and
owers). The efficacy and safety of hawthorn extract WS
442 (900 and 1,800 mg) were evaluated in a 16-week
andomized, controlled trial in 209 patients with NYHA
unctional class III heart failure. The investigators found a
ose-dependent effect of WS 1442 on enhancing exercise
apacity and reducing heart failure-related signs and symp-
oms. The preparation was shown to be well-tolerated and
afe (204). A recent pharmacokinetic study was conducted
n 8 healthy subjects consuming 0.25 mg digoxin alone or
ith hawthorn extract WS 1442, which demonstrated no
ignificant alterations in the pharmacokinetic parameters for
igoxin (205). Clinical trials are underway in the U.S. to
valuate further the safety and efficacy of hawthorn in
atients with heart failure.
Hawthorn may offer some advantages over digoxin in
ild heart failure. Compared to digitalis, hawthorn has a
ider therapeutic range, lower risk in case of toxicity, has
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July 5, 2005:184–221 ACCF Complementary Medicine Expert Consensus Documentess of an arrhythmogenic potential, is safer to use in renal
mpairment, and can be safely used with diuretics and
axatives (200). However, hawthorn can markedly enhance
he activity of digitalis (206), and care should be taken when
ombining it with beta-blockers and class III antiarrhythmics.
inkgo biloba (ginkgo leaf extract). Ginkgo has been
sed for relief of intermittent claudication in patients with
eripheral arterial occlusive disease. Ginkgo leaf, obtained
rom the Ginkgo biloba tree, and its extracts, or GBE,
ontain several bioactive constituents including flavonoids,
erpenoids, and organic acids. As with other phytomedi-
ines, several constituents of ginkgo extracts may contribute
o its therapeutic effect. The mechanism of benefit is
nknown. Two meta-analyses of the efficacy of ginkgo leaf
xtract for the treatment of intermittent claudication con-
luded that only modest benefits resulted from its use
207,208). In the meta-analysis performed by Pittler and
rnst (207), eight randomized, placebo-controlled, double-
lind studies involving a total of 415 participants were
valuated. All of the studies used pain-free walking distance
s the primary outcome measure. Several different formula-
ions of ginkgo were used with doses ranging from 120 to
60 mg a day. The majority of trials lasted 24 weeks.
tatistical pooling of the results from the eight trials showed
hat ginkgo significantly increased pain-free walking dis-
ance by 34 m. The clinical relevance of this increase is
nclear.
Ginkgo is considered relatively safe, with a few docu-
ented adverse effects being mild gastrointestinal upset and
eadache. Ginkgo has been reported to increase the risk of
leeding. The concomitant use with aspirin, non-steroidal
nti-inflammatory drugs (NSAIDs), and anticoagulants,
uch as warfarin and heparin, is not advised. Ginkgo can
ncrease blood pressure in patients taking thiazide diuretics
209). Ginkgo does not appear to interact or adversely affect
oncomitant therapy with cardiac glycosides, and it appears
o provide a small benefit in the treatment of peripheral
rterial disease.
orse chestnut (Aesculus hippocastanum). Horse chestnut
eed extract (HCSE) contains escin, a triterpene glycoside,
nd the toxic glycoside aesculin, a hydroxycoumarin deriv-
tive that is used to treat venous insufficiency (210). A
ystematic review of 14 randomized, placebo-controlled
rials (a total of 1,071 subjects) was recently completed
valuating the efficacy of HCSE for the treatment of
hronic venous insufficiency. The HCSE was found to be
uperior to placebo and as effective as compression therapy
n decreasing lower leg volume and leg circumference at the
alf and ankle. Symptoms such as leg pain, pruritus, and
eeling of fatigue and tenseness were also reduced (211).
ide effects are uncommon, but gastrointestinal irritation
nd toxic nephropathy may occur (212).
Contraindications to use include hypersensitivity to escin
r horse chestnut and renal or hepatic impairment (213). At
resent there is no human drug interaction data available,
ut the increased risk of bleeding due to the naturally yccurring coumarin constituents is possible. Also, HCSE
as been suspected of causing hypoglycemic effects (209).
he German Commission E has approved the use of
CSE in chronic venous insufficiency. It may be effective in
hat role.
uggulipid (guggul gum). Guggulipid has a long history
f use in Ayurvedic medicine, which is an ancient Indian
ystem that uses an integrated approach (diet, lifestyle,
erbs, exercise, and meditation) to the prevention and
reatment of illness by maintaining harmony among the
ind, body, and forces of nature. Both guggul and its
urified extracts have been used as hypolipidemic agents in
atients with ischemic heart disease, hypercholesterolemia,
nd obesity (214). Clinical studies performed in India have
emonstrated that 25 mg of guggulsterone extracts t.i.d.
ay be an effective treatment for hypercholesterolemia and
ypertriglyceridemia. Reductions in total cholesterol levels
f approximately 24% and reductions in triglycerides of 16%
o 23% have been reported (215,216). The majority of these
rials were not randomized.
In one randomized, controlled study of 125 hyperlipid-
mic patients, a standardized extract of guggulsterone was
ompared with clofibrate with mean reductions in serum
holesterol and triglycerides of 11% and 16%, respectively
217). In the first randomized, controlled trial of guggulipid
utside of India, 103 healthy adults with hypercholesterol-
mia given 1,000 or 2,000 mg guggulipid containing 2.5%
uggulsterones experienced no improvement in their lipid
evels. A hypersensitivity rash was reported in a small
umber of subjects (218). Effects of guggulipids on HDL
ere mixed. A standard dose is 75 to 100 mg of guggul-
terones daily divided into three doses. Guggulipids can
ause gastrointestinal upset, headache, mild nausea, belch-
ng, hiccups (209), and rash (218). Concomitant oral ad-
inistration can reduce propranolol and diltiazem bioavail-
bility and might reduce the therapeutic effects of these
rugs (219). Although in vitro studies suggest a plausible
echanism of action for guggulipid as a cholesterol-
owering agent (220), definitive safety and efficacy data are
acking.
ed yeast rice (Monascus purpureas). Red yeast is the rice
ermentation product of a mixture of several species of
onascus fungi, principally Monascus purpureas. It contains
onacolin K (lovastatin, mevinolin) and other HMG-CoA
eductase inhibiting compounds. Red yeast has been used to
educe cholesterol levels (221,222). In a 12-week placebo-
ontrolled study conducted in the U.S. in 83 healthy
ubjects with hyperlipidemia (222), 2.4 g of red yeast rice
ignificantly reduced total cholesterol by 16%, LDL choles-
erol levels by 22%, and total triglycerides by 7% compared
ith placebo. No serious side effects were reported, but
dditional longer-term studies are needed.
Red yeast should be treated as an HMG-CoA reductase
nhibitor, with all the possible side effects, drug interactions,
nd precautions associated with this class of drugs. Red
east rice is no longer marketed with standardized lovastatin
l
w
o
P
t
o
s
a
b
r
t
m
c
2
T
p
c
w
g
h
h
e
d
m
E
a
h
i
d
s
a
r
c
e
p
l
e
t
c
t
a
s
2
p
C
s
w
(
h
a
w
c
O
o
n
p
o
h
O
d
t
s
r
t
s
h
n
H
T
h
a
T
B
C
C
E
G
G
K
W
Y
R 2–6 (2
196 Vogel et al. JACC Vol. 46, No. 1, 2005
ACCF Complementary Medicine Expert Consensus Document July 5, 2005:184–221evels in U.S. owing to legal issues, and it is now sold
ithout lovastatin levels declared. Because of the availability
f statins, its use is not recommended.
olicosanol. Policosanol is a sugar cane extract that con-
ains a mixture of aliphatic alcohols. Lipid-lowering effects
f policosanol have been shown in a variety of animal
pecies; however, little is known about its mechanism of
ction or its exact composition. Over 1,000 subjects have
een studied for periods of six weeks to one year in 15
andomized, placebo-controlled trials using policosanol (5
o 20 mg per day) for lipid lowering. At doses of 10 to 20
g per day, significant reductions were observed for total
holesterol (17% to 21%) and LDL cholesterol (21% to
9%) with increases in HDL cholesterol (8% to 15%) (223).
here are no data on efficacy determined by clinical end
oints. Although policosanol appears to be well-tolerated,
aution should be exercised when combining policosanol
ith antiplatelet or anticoagulant agents, including garlic,
inkgo, and high doses of vitamin E (224), as policosanol
as been shown to inhibit platelet aggregation in both
ealthy and diseased patients (225). The majority of the
xisting studies have been conducted in Cuba, and indepen-
ent verification is needed before its use can be recom-
ended.
phedra (Ma huang). Ephedra, together with its principal
lkaloid ephedrine, was one of the first of the Chinese
erbal medicines to be used in Western medicine. Ephedra
s used to treat bronchospasm, asthma, bronchitis, allergic
isorders, and nasal congestion, or as a central nervous
ystem stimulant (209). Ephedrine acts by stimulating
lpha, beta-1, and -2 adrenergic receptors, and indirectly by
eleasing norepinephrine from body stores. The cardiovas-
ular effects of ephedrine last 10 times longer than those of
pinephrine and consist primarily of increased heart rate and
eripheral vascular resistance. Ephedrine and related alka-
oids have been associated with adverse cardiovascular
able 1. Herbs Containing Stimulants
Ingredient
itter orange (Citrus aurantium) Weight loss, nasal con
ola nut (1% to 3.5% caffeine) Short-term relief of m
ountry mallow (Heartleaf)
(0.8 to 1.2% ephedrine)
Weight loss to burn fa
sinus, allergy, asthm
phedra (Ma huang) alkaloid constituents
contain ephedrine and pseudoephedrine
Diseases of respiratory
bronchitis, nasal con
reen tea (2% to 4% caffeine) Improves cognitive per
cholesterol and trigl
uarana (2.5% to 7% caffeine) Central nervous system
enhance athletic per
hat Depression, fatigue, ob
ahoo root bark (Euonymus atropurpiuretus)
(2% to 4% caffeine)
Indigestion, stimulates
erba mate (0.2% to 2.0% caffeine)
(contains theophylline and theobromine)
Appetite suppressant, m
eprinted with permission from Nykamp DL, et al. Ann Pharmacother 2004;38:81vents, including acute MI, severe hypertension, myocardi- his, and lethal cardiac arrhythmias. Dietary supplements that
ontain ephedra alkaloids were widely promoted and used in
he U.S. for weight loss and increased energy. Their use was
ssociated with a number of adverse events, including MI,
troke, arrhythmias, and death (226), and in December
003 the FDA announced a ban on the sale of ephedra
roducts in the U.S. Of developing concern is the herbal
itrus aurantium, or bitter orange, which contains similar
timulant amines as ephedra and is now being marketed in
eight loss products. The Joint National Committee
JNC)-7 guidelines list it as a possible cause of resistant
ypertension (227). One case report of acute MI has been
ssociated with its use as contained in a multi-ingredient
eight loss product. Table 1 provides a list of herbs
ontaining stimulants.
leander (Nerium oleander/Thevetia peruviana). Oral
leander was once used for treating mild heart failure, but is
ow considered too dangerous for medicinal use (209). All
arts of the oleander plant contain the cardiac glycosides
leandrin, oleandroside, nerioside, and digitoxigenin, which
ave positive inotropic and negative chronotropic actions.
leander poisoning resembles digitalis toxicity, with pre-
ominant symptoms of nausea and vomiting, and cardiac
oxicity with conduction delays that may last up to three to
ix days. Reports suggest that yellow oleander toxicity can be
eversed by infusion of antidigoxin Fab fragments. Use of
his herb is contraindicated in patients on digoxin and
hould not be used with other cardiac glycoside-containing
erbs (209). In view of the availability of digoxin, its use is
ot recommended.
erb-Drug Interactions: What We Need to Know
he increased use of herbal and phytomedicines by both
ealth professionals and consumers has raised questions
bout herb-supplement and herb-drug interactions because
Adverse Cardiac Effects
n Cardiovascular toxicity, hypertension
and physical fatigue Arrhythmias, increased heart rate,
palpitations
rease energy, impotence,
nchitis
Arrhythmias, increased blood pressure,
palpitations, tachycardia
(bronchospasm, asthma,
n), appetite suppressant
Increased heart rate, diastolic and systolic
blood pressure
nce, diuretic, lower
es
Arrhythmias, increased heart rate,
palpitations
ulant, weight loss,
nce, reduces fatigue
Increased heart rate, central nervous system
stimulant
Increased blood pressure, palpitations,
tachycardia
roduction Shortness of breath, circulatory problems,
large quantities affect the heart
l stimulant Arrhythmias, increased heart rate
27).Use
gestio
ental
t, inc
a, bro
tract
gestio
forma
ycerid
stim
forma
esity
bile p
entaerbs are making a resurgence in the U.S. market. Kaufman
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onprescription drugs in the U.S. population, noting that:
14% of the population took supplements and herbals over
the prior week
16% of prescription drug users also took herbs or sup-
plements
40% of the population used one or more mineral or
vitamin supplements
In 1997, an estimated 15 million adults took prescription
edications along with herbal remedies and/or high dose
itamins (229). These individuals are potentially at risk for
dverse herb-supplement or herb-drug interactions. The
ollowing tables delineate possible drug interactions with
erbal or botanical products. Table 2 lists herbs that may
otentiate the effect of cardiac glycosides and antiarrhyth-
ics. Table 3 lists the potential adverse effects of herbal
emedies and their major constituents. Table 4 lists poten-
ial interactions between some herbal medicinal products
nd cardiovascular drugs. Table 5 lists the interference of
erbal products in therapeutic drug monitoring.
ummary of recommendations for bioactive food compo-
ents and dietary supplements. Supplements/interventions
hat can be recommended
. Omega-3 supplements 1 to 2 g per day if insufficient
omega-3 intake from fish
. Stanol/sterol ester margarines (2 g per day)
. Soluble fiber (5 to 20 g per day)
. Soy foods and soy protein (equivalent to 25 g soy protein
daily
Possibly useful for indications noted
. Moderate alcohol intake (1/2 to 2 drinks per day—a
drink is 5 oz of wine, 12 oz of beer or 1.5 oz of 80 proof
whiskey) for cardiovascular risk reduction
. Tea (1 to 2 cups daily) for cardiovascular risk reduction
. Recommended dietary intake of magnesium (RDA
adult men 420 mg; women 320 mg daily). Consider
supplementation for those at risk (poor dietary intake or
conditions that increase renal magnesium losses).
. Folic acid supplementation (plus vitamins B6 and B12) if
homocysteine is elevated.
Cannot recommend at this time (for some individuals in
able 2. Loss of Serum Potassium, Which May Potentiate the
ffects of Cardiac Glycosides and Antiarrhythmics
(Potassium deficiency increased by the simultaneous use of thiazide
diuretics, corticosteroids, or licorce root)
Laxatives containing anthraquinone glycosides with laxative effects:
Senna fruit and leaf (Cassia senna)
Aloe latex (aloe vera or aloe ferox)
Buckthorn bark and berry
Cascara sagrada bark (Rhamnus purshiana)
Rhubarb rootome situations, probably not harmful). Folic acid supplementation if homocysteine is not ele-
vated for vascular disease
. Garlic for lipid lowering
. Soy isoflavones for lipid lowering
. L-arginine supplementation for nutritional support
. CoQ10 for nutritional support
. Hawthorn for mild heart failure
. Ginkgo biloba for peripheral vascular disease
. HCSE for peripheral vascular disease
Supplements/interventions not recommended (possibly
armful)
. Levels exceeding the upper tolerable limits (IOM, 2001)
able 3. Potential Adverse Effects of Herbal Remedies and
heir Major Constituents*
ardiotoxicity Neurotoxicity or Convulsions
conite root tuber Aconite root tuber
erbs rich in cardioactive
glycosides
Alocasia macrorthiza root tuber†
Artemisia species rich in santonin
erbs rich in colchicine Essential oils rich in ascaridole
eigongteng Essential oils rich in thujone
icorice root Ginkgo seed or leaf‡
a huang Herbs rich in colchicine
okeweek leaf or root Herbs rich in podophyllotoxin
cotch broom† Indian tobacco herb
quirting cucumber† Kava rhizome†
Ma huang
epatotoxicity Nux vomica
ertain herbs rich in anthranoids Pennyroyal oil
ertain herbs rich in
protoberberine alkaloids
Star fruit
Yellow jessamine rhizome
haparral leaf or stem
ermander species Renal Toxicity
reen tea leaf† Beta-aescin (saponin mixture
from horse-chestnut seed)erbs rich in coumarin
erbs rich in podophyllotoxin Cape aloes†
erbs rich in toxic pyrrolizidine
alkaloids
Cat’s claw†
Certain essential oils
mpila root Chaparral leaf or stem†
ava rhizome Chinese yew
ombucha Herbs rich in aristolochic acids
a huang Impila root
ennyroyal oil Jering fruit
kullcap pennyroyal oil Squirting cucumber†
oy phytoestrogens† Star fruit
The full version of this table is available from the National Auxiliary Publications
ervice (NAPS). (See NAPS document no. 05609 for 33 pages of supplemental
aterial. To order, contact NAPS, c/o Microfiche Publications, 248 Hempstead
pke., West Hempstead, NY 11552.) Adverse effects of multiple-herb therapies are
ot included. Case reports do not always provide adequate evidence that the remedy
n question was labeled correctly. As a result, it is possible that some of the adverse
vents reported for a specific herb were actually due to a different, unidentified
otanical or another adulterant or contaminant. †A single case was reported without
eference to previous cases. ‡Convulsions have been observed after large doses of
inguo (ginkgo seed), a traditional Asian food and medicine, which contains the
onvulsive agent 4=-O-methylpyridoxine (MPN) (230,231). Recently, anecdotal
eports have associated ginkgo-containing preparations available on the Western
arket with seizures (232), and these adverse events have also been reported in
atients with seizure disorders stabilized by valproate (233). How Western ginkgo
reparations might induce seizures is still unclear. MPN has been detected in ginkgo
eaf and preparations that contain ginko, but usually at subtoxic levels (234). Reliable
nformation concerning herb-drug interactions can be obtained from the following
eb sites: www.Naturaldatabase.com, www.herbmed.org. and www.herbalgram.org.for vitamins C (2,000 mg/day) and E (1,000 mg/day);
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Herbal Medicine†
Usage or Relevant
Pharmacological Effect‡ Potential Interaction
donis (Adonis vemalis) Digitalis-like Contains cardiac glycosides and may enhance other such drugs;
increases (adverse) effects of quinodine, calcium saluretics, laxatives,
glucosteroids, beta-blockers, calcium channel blockers, and digitalis
loe vera (Aloe barbadensis) Various, e.g., wound healing
(topical) or antidiabetic (oral)
With chronic use, potentiation of cardiac glycosides or antiarrhythmic
drugs due to loss of potassium
rnica (Arnica montana) Wound healing Decreases effects of antihypertensives and anticoagulants
earberry (Arctostaphylos uva ursi) Diuretic Increases effects of cardiac glycosides through potassium depletion: may
alter blood level of drugs metabolized in the liver due to hepatic
enzyme induction
ilberry (Vaccinium myrtillus L) Circulatory disorders Increases effects of anticoagulants
lack cohosh (Cimicifuga racemosa) Estrogenic Increases effects of antihypertensives
lue cohosh (Caulophyllum) Smooth muscle stimulant Decreases effects of antihypertensives
ogbean (Menyanthes trifoliate) Diuretic, analgesic Increases effects of anticoagulants
oldo (Bolodo folium) Diuretic Increases effects of cardiac glycosides (potassium depletion)
room (Cystisus scoparius) Antiarrhythmic, diuretic Increases effects of antidepressants, beta-blockers, and cardiac
glycosides: induces circulatory collapse with quinidine, haloperidol,
or moclobemide
uchu (Barosma betulina) Diuretic Increases effects of anticoagulants and cardiac glycosides (potassium
depletion)
uckthorn (Rhamnus cathartica) Laxative, cathartic Causes loss of potassium with chronic use; potentiates cardiac
glycosides or antiarrhythmic drugs
utchers broom (Busus aculeatus) Venoconstriction Decreases effects of alpha-blockers
apsicum (Capsicum anuum L) Appetite stimulant May interfere with antihypertensives and MAO inhibitors; can
stimulate the hepatic metabolism of drugs
ascara (Rhamnus purshiana) Laxative, cathartic Causes loss of potassium with chronic use; potentiates of cardiac
glycosides or antiarrhythmic drugs
ats claw (Uncaria tomentosa) Anti-inflammatory Increases effects of anticoagulants and antihypertensives; can interfere
with protein-based drugs and chemotherapy
hamomile
(Matricaria chamomilla)
Spasmolytic. anti-inflammatory May potentiate effects of anticoagulants through its coumarin content
inchona (Cinchonae cortex) Dyspepsia Increases effects of anticoagulants
oltsfoot (Tussilaga farfara) Asthma, bronchitis May antagonize antihypertensives: increases hepatotoxicity of other
drugs
ordyceps (Cordyceps sinensis) Tonic, stress management Increases effects of anticoagulants and MAO inhibitors
owslip (Primula veris) Sedative Increases effects of diuretics and antihypertensives
andelion (Taraxatum officinale) Laxative, diuretic Increases effects of antihypertensives, diuretics, and hypoglycemics
everfew (Tanacetum parthenium) Migraine prevention Increases effects of warfarin
enugreek
(Trigonella foenum-graecum)
Hypocholesterinemic Increases effects of anticoagulants and hypoglycemics: may decrease
absorption of other drugs
igwort (Scrophularia nodosa) Antibacterial, anti-inflammatory Increases effects of beta-blockers, calcium channel blockers, and cardiac
glycosides
umitory (Fumaria officinalis) Antibacterial, diuretic, laxative Increases effects antihypertensives, beta blockers, calcium channel
blockers, and digoxin
inseng, Siberian
(Eleutherococcus senticosus)
Stimulant May interact with cardiac drugs, hypo- and hypertensives, and
antihypoglycemics
oldenseal (Hydrastis canadensis) Anti-inflammatory, antimicrobial Increases effects of antihypertensives, calcium channel blockers, and
digoxin; may decrease anticoagulant effects; many herbalists believe
that goldenseal generally enhances the activity of other drugs
ossypol (Gossypium hirsutum) Antifertility drug May lead to potassium depletion with diuretics; can enhance renal
toxicity of other drugs
awthorn (Crataegus laevigata) Digitalis-like Can increase hypotensive effects of nitrates, antihypotensives, cardiac
glycosides, and CNS stimulants
orse chestnut
(Aesculus hippocastanum)
Anti-inflammatory Increases effects of anticoagulants
orsetail (Equisetum arvense) Diuretic Increases effects of CNS stimulants and diuretics
lex (Ilex paraguarensis) Diuretic, analgesic Can increase effects of diuretics; hepatic microsomal enzyme inhibitors
may decrease clearance and cause toxicity
ndian snake root (Rauwolfia) Hypotensive Cardiac glycosides, bradycardiabarbiturates (and other CNS
depressants); potentiation; levodopa; neutralization; extrapyramidal
symptoms; sympathomimetics; hypertension
rish moss (Chondrus crispus) Demulcent for ulcers or gastritis Increases effects of anticoagulants and antihypertensives
elp (Laminaria digitata) Antitumour effects, antiobesity Increases effects of anticoagulants and antihypertensivesContinued on next page
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July 5, 2005:184–221 ACCF Complementary Medicine Expert Consensus Documentand beta-carotene supplementation not recommended;
limit to food sources.
. Ephedra, oleander, and other herbs/botanicals with
well-defined contraindications to cardiovascular drug
and/or CVD conditions.
elated Alternative Therapy
helation. Chelation therapy is a form of alternative med-
cine utilized in the treatment of atherosclerotic CVD. Over
able 4 Continued
Herbal Medicine†
Usage or Relevant
Pharmacological Effect‡
hella (Ammi visnaga) Spasmolytic
ily of the valley
(Convallaria majalis)
Congestive heart failure
ovage (Levisticum officinale) Diuretic
ettle (Urtica dioica) Diuretic
ight-blooming cereus
(Selenicereus grandiflorus)
Digitalis-like
arsley (Petroselinum crispum) Hypotensive
au d’arco (Tabebuia impetiginosa) Aphrodisiac
ineapple (Anannas comosus) Constipation, jaundice, obesity,
antiulcer
lantains or psyllium
(Plantago lanceolata)
Bulk laxative
oplar (Populus alba) Anti-inflammatory
rickly ash
(Zanthoxylum americanum)
Antiflatulent
umpkin seed (Curcubita) Anthelmintic, diuretic
ed clover (Trifolium partense) Estrogen-like
arsaparilla
(Sarsaparilla aristochiifolia)
Diuretic, psoriasis
enna (Cassia) Laxative
orrel (Rumex acetosella) Antiseptic, diuretic
t John’s wort
(Hypericum perforatum)
Antidepressant
trophantus (Strophantus kombe) Digitalis-like
weet clover (Meliloti herba) Venous insufficiency
onka bean (Dipteryx odorata) Aphrodisiac
urmeric (Curcuma longa) Cancer prevention
ervain (Verbena officinalis) Antirheumatic
illow (Salix alba) Analgesic
oodruff (Asperula odorata) Diuretic
arrow (Achillea millefolium) Antispasmodic, anti-inflammatory
ardiovascular adverse effect of herbal medicines: a systematic review of the recent l
ata extracted from Fugh-Berman A. Lancet 2000;355:134–8 (236). *Not all effects
Not comprehensive.
CNS  central nervous system; MAO  monoamine oxidase.00,000 patient visits were made for chelation therapy in the a.S. in 1997. Chelation therapy consists of a series of
ntravenous infusions containing disodium ethylene diamine
etraacetic acid (EDTA) in combination with other sub-
tances, such as vitamins. Use of EDTA has been found to
e effective in chelating and removing toxic heavy metals
rom the blood (238). It is purported that the removal of
olyvalent cations, notably calcium ions, can lead to the
egression of atherosclerotic plaques by a yet undefined
echanism. Use of EDTA chelation therapy is FDA-
Potential Interaction
Increases effect of anticoagulants, calcium channel blockers, and other
antihypotensive drugs
Increases effects of quinodine, calcium, salureties, laxatives,
glucosteroids, beta-blockers, calcium channel blockers, and digitalis
May potentiate effects of anticoagulants
May potentiate effects of other diuretics
Increases effects of hypoglycemics; may enhance effects of cardiac
glycosides, angiotensin-converting enzyme inhibitors,
antiarrhythmics, beta-blockers, and calcium channel blockers
Increases effects of antihypertensives; enhances toxicity of MAO
inhibitors
Increases effects of anticoagulants; decreases effects of iron supplements
Overanticoagulation through coumarin contents; may antagonize effects
on bradykinin with angiotensin-converting enzyme inhibitors
(bromelain)
Can delay absorption of other drugs (e.g., lithium); increases effects of
cardiac glycosides
Increases effects of anticoagulants
Increases effects of anticoagulants
Can increase effect of diuretics
Increases effect of anticoagulants on digoxin; interferes with oral
contraceptives
Increases absorption of digitalis, glycosides, bismuth; accelerates
elimination of hypnotics
Causes loss of potassium with chronic use; increases effects of cardiac
glycosides, antiarrhythmic drugs, calcium channel blockers,
clamodium antagonists, and indomethacin; may decrease effects of
senna preparations
Increases effects of other diuretics; increases hepatotoxicity of other
medications
Hepatic enzyme inducer; increases activity of P-glycoprotein, thereby
reducing plasma levels of many drugs
Contains cardiac glycosides and may enhance effects of other such
drugs
Contains coumarins, which may enhance effects of anticoagulants
Increases effects of anticoagulants; increases hepatotoxicity of other
drugs
Enhances effects of antiplatelet drugs; decreases effects of
immunosuppresants
Increases effects of anticoagulants and hypnotics
Causes transient potentiation of phenytoin; increases effects of
anticoagulants
Contains coumarins, which may enhance effects of anticoagulants
Increases effects of anticoagulants, antihypertensives and CNS
depressants; increases hepatotoxicity of other drugs
re. Reprinted with permission from Ernst E. Can J Cardiol 2003;19:818–27 (235).
e interactions (some are, for instance, additive effects). †Plant source in parentheses.iteratu
are trupproved in treating lead poisoning and toxicity from other
h
c
c
A
o
s
(
c
o
s
m
“
a
c
t
i
c
L
l
o
a
T
t
d
t
t
c
c
a
I
T
R
r
A
p
T
C
C
G
H
H
H
S
C
M
R LR, e
; INR
200 Vogel et al. JACC Vol. 46, No. 1, 2005
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helation therapy to treat CAD.
The bulk of the evidence supporting the use of EDTA
helation therapy is in the form of case reports and case series.
systematic review on chelation therapy for peripheral arterial
cclusive disease has shown that chelation therapy is not
uperior to placebo and is associated with considerable risks
239). At present, the benefit of chelation therapy remains
ontroversial as highlighted by a recent Cochrane Review (240)
f five randomized controlled studies in small numbers of
ubjects evaluating outcomes of disease severity and subjective
easures of improvement.
The ACC position statement reapproved in 1990 states
that there is insufficient scientific evidence to justify the
pplication of chelation therapy for atherosclerosis on a
linical basis. At the present time, therefore, chelation
herapy for atherosclerosis should be applied only under an
nvestigation protocol.”
In an effort to advance the evidence base for the use of
helation therapy, the NCCAM and the National Heart,
able 5. Laboratory Analysis and Treatment Guidelines for Spec
Herbal Preparation Suggested Laborat
ardiac toxins
Ch’an Su Serum digoxin, potassium
Foxglove Serum digoxin, potassium
Oleander Serum digoxin, potassium
Squill Serum digoxin, potassium
entral nervous system toxins
Henbane None
Jimsonweed (Datura) None
Mandrake None
astrointestinal toxins
Aloe Serum electrolytes
Buckthorn Serum electrolytes
Cascara Serum electrolytes
Fo-Ti Serum electrolytes
Senna Serum electrolytes
eavy metals Ag, As, Au, Cd, Cr, Cu,
Abdominal radiograph
ematologic toxins
Dong Quai INR
Tonka bean INR
Woodruff INR
epatotoxins
Pennyroyal oil AST/ALT
Pyrrolizidine alkaloids AST/ALT
alicylates
Medicated oils, etc. Serum salicylate
ellular toxins
Apricot pits (cyanide) Lactate
Autumn crocus (colchine) WBC, BUN
Elder (cyanide) Lactate
Periwinkle (vincristine) WBC, BUN
Pododphyllum (podophylline) WBC, BUN
iscellaneous
Licorice Serum potassium
Quinine None
eproduced with permission from Toxicologic Emergencies, 7th edition, Goldfrank
ALT  alanine aminotransferase; AST  aspartate; BUN  blood urea nitrogenung, and Blood Institute (NHLBI) have launched the first parge-scale clinical trial to determine the safety and efficacy
f EDTA chelation therapy in individuals with coronary
rtery disease. The five-year Trial to Assess Chelation
herapy (TACT) will involve over 2,300 patients at more
han 100 research sites across the country. The study will
etermine whether EDTA chelation and/or high-dose vi-
amin supplements improve event-free survival, whether
hese are safe for use, improve the quality of life, and are
ost-effective. The primary end point in the trial will be a
omposite of death, MI, stroke, hospitalization for angina,
nd coronary revascularization.
II. MIND/BODY AND PLACEBO
he Mind/Body Relationship and its Correlation to CVD
eviewing the mind/body relationship and its clinical cor-
elates to CVD is a union of both the social and biological.
lthough physicians easily grasp measurable physiological
henomena (e.g., the concept of acid production, blood
erbal Preparation and Their Critical Contaminants
nalysis Antidote
Digoxin Fab
Digoxin Fab
Digoxin Fab
Digoxin Fab
Physostigmine
Physostigmine
Physostigmine
Potassium repletion
Potassium repletion
Potassium repletion
Potassium repletion
Potassium repletion
b, Th, or Zn Metal chelator
Vitamin K1
Vitamin K1
Vitamin K1
N-acetylcysteine
None available
Sodium bicarbonate, multiple dose activated
charcoal, hemodialysis
Cyanide antidote kit
? Glutamic acid
Cyanide antidote kit
? Glutamic acid
? Glutamic acid
Potassium repletion
Sodium bicarbonate, magnesium
t al. McGraw-Hill Medical Publishing Division (237).
 international normalized ratio; WBC  white blood cell.ific H
ory A
Hg, Pressure elevation, and the angiographic narrowing of a
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ocial relationships, isolation, anger, depression, and their
anifestation in disease. Sterling and Eyer (241) have
llustrated how the development of modern society is
ssociated with a disruption of human relationships. These
isruptions cause chronic psychological arousal, which is
efined as stress. The body’s physiological mechanisms are
ltered by chronic psychological arousal and this leads to
athology and disease.
The function of arousal is to help the individual “cope”
ith environmental demands. Coping may be defined as
contending” or “struggling.” This behavior frequently re-
uires excess physical or emotional energy to deal with a
ifficult situation. Studies have shown that patients entering
hospital for diagnostic tests have elevated norepinephrine,
pinephrine, cortisol, and growth hormone levels (242–
45). Because these patients have little control over their
ituation, there is little effective coping behavior. Under
hese circumstances, in which limited control over the
nvironment is possible, the stress hormones are maximized.
ikewise, students during examination periods demonstrate
rise in cortisol, epinephrine, serum blood sugar, choles-
erol, and blood pressure levels. Under exam stress, these
ame students exhibit a decline in white blood cells
242,243,245–249). This drop in white blood cells in part
xplains the high rate of physical illness under stressful
ituations. Tax accountants have been shown to have large
ncreases in serum cholesterol (independent of diet) and a
ecrease in blood clotting time during tax season (250).
rousal, and as a consequence stress, will be high not only
mong individuals with little control over life circumstances,
ut also among individuals with a high demand for perfor-
ance. Arousal that results from a lack of control will
requently manifest with anger or fear. Although high-
emand situations are frequently accompanied by anxiety,
hey may result in extreme pleasure if the coping style is
uccessful. However, this success in the end does not mean
hat the metabolic costs to the body are less.
mpact of Stress on CVD Risk Factors
n the Framingham Heart Study (251), hypertension was
nvolved in over 80% of all cardiovascular deaths. In addi-
ion, hypertension was at least twice as strong a predictor of
eath as smoking or elevated blood cholesterol. Over 50
illion Americans are currently hypertensive. In about 5%,
specific pathology such as a renal artery stenosis can be
dentified. In the remaining 95%, the blood pressure in-
rease is not attributed to a specific pathology. Different
echanisms can contribute to the development of hyper-
ension. Acute arousal leads to sympathetic stimulation and
n increase in cardiac output. When arousal is maintained
or long periods of time, the elevation in blood pressure
emains even if the inciting stimulus is removed. At this
tage, the hypertension is not sustained by increased cardiac
utput but by increased vascular resistance.
Stress may lead to hypertension through repeated blood tressure elevations and by increasing the amount of vaso-
onstricting hormones. Stress factors leading to hyperten-
ion include job strain, social environment, emotional stress,
nd white coat hypertension. Overall, studies conclude that,
lthough stress does not directly cause hypertension, it can
learly affect its development. Stress leads to sympathetic
ervous system activation with excessive amounts of corti-
ol, epinephrine, and aldosterone. The combination of
ncreased cardiac output and vasoconstriction may tran-
iently raise blood pressure. Feelings of frustration, exhaus-
ion, and helplessness can activate the pituitary and adre-
ocortical hormones. Non-pharmacological treatments to
anage stress such as meditation, acupuncture, biofeedback,
nd music therapy have been found to be effective in
ecreasing blood pressure and the development of hyper-
ension (252).
Although not a substitute for pharmacological therapy,
ertain non-drug therapies offer support for individuals with
ypertension. Steelman (253) studied the effect of tranquil
usic on blood pressure and anxiety in surgery patients. The
xperimental group listened to music during the intraoper-
tive period. The control group received usual care. Music
ppeared to reduce blood pressure in the experimental
roup. Pender (254) studied the effect of progressive muscle
elaxation (PMR) training in hypertensive patients. Those
ndividuals who received PMR training reported less anxi-
ty. Decreased anxiety correlated with decreased systolic
lood pressure. Older African-Americans who were taught
he transcendental meditation technique had a significant
eduction in diastolic and systolic blood pressure (255).
Diabetes, like hypertension, remains an important risk
actor for the development of CVD. Chronic arousal can
ontribute to diabetes in two ways. With arousal, there is an
ncrease in catabolic hormones, most notably epinephrine,
ortisol, growth hormone, and glucagon. These hormones
ntagonize the actions of insulin by mobilizing glucose, fatty
cids, and protein breakdown. Furthermore, glucagon and
orepinephrine act to suppress the secretion of insulin. The
esulting hyperglycemia, hyperinsulinemia, and hyperlipid-
mia all accelerate pathology.
In addition to hypertension and diabetes mellitus, studies
inking stress and cholesterol date back to the 1950s. These
lder studies suggest that stress associated with time pres-
ure, repetitive assembly line work, and increased responsi-
ility may raise serum cholesterol (250,256,257). Both
ortisol and epinephrine have been linked in humans to
erum cholesterol elevation. In many animal experiments,
tress has accelerated atherosclerosis. Rabbits on a high-fat
iet when stressed with electrical stimulation over 10
onths have an increased number of atheromas in compar-
son with non-stressed controls. The administration of
pinephrine to cholesterol-fed rabbits further intensifies
ipid infiltration of the aortic intima. As mentioned previ-
usly, accountants show continuous monthly rises in cho-
esterol, despite maintaining a constant diet, which peaks at
he end of the fiscal year (250).
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growing body of evidence suggests that depression may
redispose to cardiovascular events (258). Individuals with
ental stress during daily life have twice the risk of
yocardial ischemia. In addition, those patients with
ost-MI depression have higher mortality rates than non-
epressed controls. Depression is common after acute MI
nd is associated with an increased risk of mortality for at
east 18 months. One reason for this higher morbidity and
ortality within the first few months following an MI is
hat depressed patients are less likely to follow recommen-
ations to reduce further cardiac events.
Ziegelstein et al. (259) found that patients who were
dentified with at least mild-to-moderate depression or
ajor depression reported lower adherence to a low-fat diet,
egular exercise, and stress management. Individuals with
ajor depression and/or dysthymia reported taking their
edication less often than prescribed. Those findings, in
art, explain why depression in the hospital is related to
ong-term prognosis in patients recovering from an MI.
In addition, acute MI patients with unstable angina who
ere identified as depressed in the hospital were more likely
o experience cardiac death or nonfatal MI than other
atients (259). The impact of depression on 430 patients
ith unstable angina (41.4% depressed) remained after
ontrolling for other prognostic factors such as left ventric-
lar ejection fraction and number of diseased vessels (260).
In addition to depression, other research suggests that
ocial support may influence prognosis following an acute
I. In a study of 887 post-MI patients, Frasure-Smith et al.
261) found that 32% had mild-to-moderate depression.
fter one year, follow-up interviews were conducted and
emonstrated that elevated Beck depression scores were
elated to cardiac mortality. The relationship between de-
ression and cardiac mortality decreased with increasing
upport. Furthermore, of those one-year survivors who were
epressed at baseline, higher baseline social support was
elated to greater than expected improvement in depression
ymptoms.
The Enhancing Recovery in Coronary Heart Disease
atients Study (ENRICHD) was sponsored by the
HLBI. The study enrolled 2,481 patients at 73 hospitals
ithin 28 days of an MI; participants had major or minor
epression, low social support, or both. Patients were
ssigned to either a “treatment” or “usual medical care”
roup (262). Cognitive therapy was provided by the treat-
ent group for six months. At the end of six months,
atients in the treatment group scored significantly better
n the Hamilton depression (57% reduction in depression
ersus 47% reduction in the usual medical care group) scale.
ikewise, patients low in social support demonstrated a 27%
mprovement in this parameter versus 18% for the usual care
roup. However, despite the treatment groups’ improve-
ent in depression and social isolation, there was nomprovement in heart disease survival.Increased use of selective serotonin reuptake inhibitors
SSRIs) and their demonstrated safety in patients with
VD raises the question of whether early pharmaceutical
reatment for depression in cardiac patients will improve
linical outcome (263–265). Yet despite this low-risk pro-
le, very little research exists regarding the benefit of SSRIs
n patients with CVD. The Sertraline Antidepressant Heart
andomized Trial (SADHART) has evaluated the efficacy
nd safety of sertraline therapy in patients with acute heart
isease without evidence of statistically significant benefit
266). Until meaningful data are obtained, the use of
ntidepressants in cardiac patients requires a weighing of
he risks versus potential benefit.
In addition to affecting lipids, enhancing weight loss and
mproving exercise tolerance, cardiac rehabilitation provides
motional support, reduces depression, improves quality of life
cores, and decreases mortality by 25% (267–271). Such
rograms serve as the logical place to screen cardiac patients for
sychosocial risk factors such as depression and anxiety. Once
dentified, appropriate intervention can be initiated.
In conclusion, although post-MI depression is a predictor
f one-year cardiac mortality, high levels of social support
ppear to decrease the magnitude of depression. High levels
f social support also predict improvements in depression
ymptoms over the first post-MI year in those individuals
ith baseline depression.
ummary of recommendations for mind/body relation-
hip. Several complementary and alternative medicine
echniques have been used as adjuncts to traditional thera-
ies in the treatment of CVD as follows:
. Coronary artery disease
1. Stress reduction
2. Meditation
3. Group support
. Arrhythmias
1. Biofeedback
2. Stress management
3. Group support
. Pre-surgery
1. Guided imagery
. Cholesterol
1. Stress management
2. Meditation
. Congestive heart failure
1. Biofeedback
2. Group support
f. Hypertension
1. Group support
2. Biofeedback
3. Meditation
4. Pet acquisition (272–277)
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Placebo,” Latin for “I shall please,” can be derived from a
evice, a drug, or complementary medicine modalities. A
lacebo is not necessarily a sham therapy but a potential
esponse due to an interaction between the intent of the healer
nd the expectations of the patient. The response can be
owerful, but the longevity of the response can vary by
ondition and type of placebo. Several reports in cardiology—
HAT (278), CHF-STAT trial (279), and the Coronary
rug Project (280)—have shown a remarkably strong effect
egarding compliance with placebo. The reduction in mor-
ality for those who take their placebo compared to those
ho are non-compliant is highly significant, but the mech-
nism (280) is unknown.
Shapiro (281) indicated that the physician was important in
he dyadic dance of healing and proposed that perhaps doctors,
ndependent of what they did, were actually potent placebos in
heir own right. He and others enumerated a number of
pecific variables that might endow some physicians with
articular curative manna: enthusiasm for treatment, apparent
arm feelings for the patient, confidence, and authority. Some
hysicians may be able to exhibit a placebo effect more
ntensely than others, but the mechanism for this and the
xtent of it are not understood.
The placebo effect has been described as a nonspecific
sychological or psychophysiologic therapeutic effect, but
his may not be correct and the response may be a crucial
ynergistic adjunct to any cardiovascular therapy. Placebos
an elicit a real and substantial response, the extent of which
s related to the type of the placebo, the condition being
reated, and the response being elicited. No multivariate
nalysis has detected which specific patient characteristics
re most associated with a profound placebo effect. The
lacebo response in major depression (282) ranges from
2% to 70% and can equal that of a drug intervention. After
ll, what occurs during psychotherapy is a form of placebo
esponse. The importance of understanding the mecha-
isms responsible for the placebo response is crucial to
nderstanding the basic nature of healing (283). Expect-
ncy, beliefs, anxiety, hope, trust, and intent can alter
utcomes regarding disease (284).
The placebo response may involve disease expression,
pecific neuroendocrine, neuronal and immune intermediary
athways, neuropeptides, enkephalins, endorphins, cholecys-
okinin, neurohormones (including glucocorticoids and prolac-
in), neurotransmitters (including 5-hydroxytryptamine, nor-
pinephrine, dopamine), and other messengers such as nitric
cid and prostaglandins. The power of expectancy of im-
rovement was emphasized by controlled trials of arthro-
copic surgery and of neurosurgery. Osteoarthritis of the
nee responds as well to arthroscopic debridement, arthro-
copic lavage, and placebo surgery. Similarly, sham neuro-
urgery improved Parkinson patients as well as cell implants
nd sham cardiovascular surgery improves patient chest pain
s often as 90% of the time (285). It is, however, difficult to muantitate the benefit of either the placebo effect or sham
rocedure.
Hrobjartsson and Gotzsche (286) suggest there is little
vidence that placebos in specific conditions, comparing no
herapy to placebo therapy, had powerful clinical effects. Yet
his is likely disease specific as many placebo-controlled
tudies showed enormous benefits of the placebo (282).
nother form of the placebo response is relief to a patient
hen serious disease is excluded. Patients who have an
valuation (“tests”) for atypical chest pain are less likely to be
isabled than those who do not have such an evaluation
287).
V. ACUPUNCTURE
cupuncture has gained increasing acceptance by the lay
ublic, partly as a result of increasing communication
etween the U.S. and China since the early 1970s (1,288).
exts on acupuncture date back to 206 BC, although the
ellow Emperor, Huang Di, the originator of traditional
hinese medicine lived in 2,697 BC (289). Acupuncture has
een used for a wide variety of conditions, but it is most
ccepted for treatment of pain (290–293). Increasing evi-
ence suggests that acupuncture may also be useful in
reating patients with neurological disease, including disor-
ers of the autonomic nervous system, hypertension, and
ther forms of CVD. The World Health Organization
WHO) has noted that acute infection and inflammation,
ysfunction of autonomic nervous system, pain, and
eripheral and central neurological diseases each repre-
ent conditions for which acupuncture may be indicated
291,292,294). The mechanism by which acupuncture is
elieved to benefit the subject is through its ability to
odulate neural activity in several regions of the brain and
hus reduce sympathetic outflow to the heart and vascular
ystem (295).
There are four areas of CVD for which acupuncture
ventually may be indicated. These include ischemic CVD,
ypertension, heart failure, and arrhythmias. Studies from
everal groups, including Ballegaard (296) and Richter
297), have examined the role of acupuncture in treatment
f patients with stable angina. Ballegaard, in an initial study,
as unable to document a decrease in angina in humans as
easured by a decrease in the rate of anginal attacks,
onsumption of nitroglycerin or exercise tolerance, compar-
ng true acupuncture to sham acupuncture (296,298); the
roup concluded that true acupuncture cannot be distin-
uished from sham acupuncture in which needles were
laced outside traditional meridians. Two other studies by
he same group showed an acupuncture-related improve-
ent in exercise capacity and rate-pressure product (299),
articularly when acupuncture reduces sympathetic neural
utflow (298). Separately, Richter (297) observed that
cupuncture exerted a beneficial effect in patients with
evere stable angina who had been aggressively treated with
edical therapy. Manual acupuncture reduced the number
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ACCF Complementary Medicine Expert Consensus Document July 5, 2005:184–221f anginal attacks per week, the severity of chest pain,
lectrocardiographic evidence of myocardial ischemia, and
ncreased the workload required to provoke angina in
atients with CAD and stable angina (297). The latter study
sed a tablet placebo control. These studies involved small
umbers of patients, were unblinded, and did not use the
ost appropriate sham controls.
Prolonged peripheral vasodilation, measured by periph-
ral thermography, occurs following electroacupuncture
297). Acupuncture or its non-invasive surrogate, transcu-
aneous electrical nerve stimulation (TENS), appears to
nfluence peripheral blood flow in patients with Raynaud’s
yndrome (300), skin flap survival in experimental prepara-
ions (301,302), and skin temperature in patients with
olyneuropathy (303). The primary form of Raynaud’s
old-induced vasoconstriction, assessed by Doppler flow-
etry and clinical symptoms, is reduced by acupuncture
ompared to sham treatment (300). Secondary forms of
aynaud’s appear to be less influenced by acupuncture.
urvival of ischemic musculocutaneous skin flaps is in-
reased in experimental preparations treated with either
anual or electroacupuncture (301,302). Similarly, patients
ndergoing reconstructive surgery who are treated with
ENS experience improved microvascular flow and reduced
dema and capillary stasis relative to placebo TENS (304).
ow-frequency TENS leads to a prolonged increase in skin
emperature in patients with diabetic polyneuropathy (303).
ost studies on the peripheral circulatory effects of acu-
uncture are small and were not blinded; confirmation of
heir observations is needed.
Several small trials suggest that hypertension may be
mproved by acupuncture (305–310). The magnitude of the
ffect of acupuncture on blood pressure in patients with
ypertension is small but significant; reductions of 5 to 10
m Hg have been noted. These and other small studies
rom outside the U.S. have led to funding of at least two
ngoing clinical trials by the NCCAM to test the hypoth-
sis that acupuncture can lower blood pressure in patients
ith hypertension.
Experimental studies indicate that acupuncture reduces
emand-induced myocardial ischemia in felines (311),
atecholamine- or stress-induced hypertension (312–315),
r genetically associated hypertension (316). These studies
lso demonstrate that acupuncture limits myocardial isch-
mia by reducing myocardial oxygen demand rather than by
ncreasing coronary blood flow in a feline model (311).
cupuncture also can inhibit ventricular extrasystoles in-
uced by stimulating the hypothalamus (317), paraventricu-
ar nucleus (317) or following administration of BaCl2
314).
The rationale for using acupuncture to treat myocardial
schemia, hypertension, and arrhythmias stems from its
bility to inhibit sympathetic outflow (316). Numerous
xperimental studies have shown that acupuncture, partic-
larly low frequency (2 to 4 Hz) electroacupuncture, causes
he release of opioids in a number of regions in the 7ypothalamus, midbrain, and medulla (290,318–323) that
re concerned with processing information that ultimately
nfluences sympathetic neural activity. Thus, by releasing
ndorphins, endomorphins, or enkephalins (324), which act
s neuromodulators that likely reduce function of excitatory
eurotransmitters, acupuncture appears to be able to inhibit
ympathetic outflow and clinical events associated with
eightened sympathetic activity. Other neurotransmitters
hat might be associated with the influence of acupuncture
n sympathetic neural activity important in cardiovascular
egulation include gamma-aminobutyric acid (GABA), se-
otonin or 5-hydroxydopamine (5-HT), acetylcholine, and
ociceptin (131). High-frequency electroacupuncture (100
z) may influence the cardiovascular system through an-
ther opioid neurotransmitter/neuromodulator, dynorphin
325).
Acupuncture can be stimulated either manually by simply
nserting a needle in an acupuncture point, then either
eaving it in place or twisting and thrusting the needle or by
timulating the needles with a small amount of electrical
urrent at low frequency (2 to 4 Hz) (312,314). Electro-
cupuncture appears to be the strongest form of acupuncture
nd can induce a long clinical response in rats lasting from
to 12 h (316). These responses have led to treatment
egimens of 30 to 45 min of acupuncture administered two
o three times per week for 2 to 4 weeks. Although there are
o well-controlled studies in humans, there is a suggestion
hat one to four courses of 10 days’ treatment with acupunc-
ure lowers blood pressure (5 to 25 mm Hg) in some (e.g.,
orderline and essential hypertension) but not in all types of
ypertension (307–310). Many practitioners use manual
cupuncture at several acupoints including acupoints within
he same spinal segment, called “segmental acupuncture,” or
combination of segmental and distant acupoints (i.e.,
uricular acupuncture). In the treatment of pain, there are
umerous variations of these techniques, including inserting
eedles at myofascial trigger points and at the specific site of
ain (326). There are no data on the efficacy of different
echniques of acupuncture with respect to cardiovascular
reatment.
Specific acupuncture points, such as the Neiguan or
usanli acupoints, overlying the median and deep peroneal
erves, respectively, have been used extensively for treat-
ent of cardiovascular abnormalities (317), although the
ssue of point specificity for treating specific organ system
ilments requires further research. The NIH has published
consensus statement indicating that a number of issues
elated to acupuncture concerning its efficacy, sham effects,
dverse reaction, acupuncture points, training and creden-
ialing, and mechanisms of action need further exploration
294).
The response to acupuncture has been suggested to be
elated to the placebo effect (293). Because placebo effects
an occur in as many as 40% of patients and because
cupuncture seems to be efficacious in only approximately
0% of patients, there appears to be a narrow window
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0% of patients) (327). Nevertheless, one mechanism of
lacebo appears to involve the endogenous opioid system
328). Most practitioners check for symptoms of tingling,
ocal warmth, heaviness, or fullness, termed DeQi, to
onfirm proper placement of needles in acupoints. Such
ymptoms indicate stimulation of underlying neural path-
ays, but do not guarantee a true acupuncture versus a
lacebo response. Although experimental preparations cir-
umvent this criticism, because the animals generally are
nesthetized, clinical investigation in the future will need to
nclude adequate sham controls to provide rigorous tests of
he acupuncture hypothesis.
Worldwide, more than 40% of physicians recommend
cupuncture to their patients and more than 15% of physi-
ians want to add this modality to their therapeutic arma-
entarium (329). Although not required for licensed phy-
icians, the practice of acupuncture by others, such as those
rained in traditional Chinese medicine (i.e., acupunctur-
sts), currently is regulated by more than 35 state boards in
he U.S. Furthermore, the FDA regulates use of the
isposable stainless steel acupuncture needles. Recently, a
orkshop held by the NHLBI and the NCCAM identified
reas of needed research in complementary medicine in
eneral and acupuncture specifically (330).
Areas of needed research in acupuncture include clinical
fficacy, mechanisms of action, and side effects. Most
uthorities agree that the risk of an adverse event resulting
rom acupuncture is small, generally below 10% if per-
ormed by physicians. However, the risk of a serious event
uch as pneumothorax, the most common severe side effect,
s significantly lower (2%), and although spinal cord lesions,
epatitis and HIV infections, endocarditis, arthritis, and
steomyelitis have been reported, they are rare. The risk of
n adverse event for non-physician acupuncturists is higher
331), but again the risk of a serious event is low.
. BIOENERGETICS (ENERGY MEDICINE)
ince ancient times, many cultures and religious disciplines
ave considered that an aura, a life force, a radiant energy
eld can emanate from, and surround, living things (332).
his poorly understood vital energy (Hindu prana, Chinese
i, chi, and Japanese ki) associated with the soul, spirit, and
ind, impinges on the potential boundaries of modern
hysics and the relationship of the mind to the physical
orld (333). Bioenergetics offers the possibility to harness a
ealing life force (334,335). The wide array of questionable
nergy-healing approaches opens the possibility of medical
uackery that can put patients with serious underlying
iseases at risk especially if standard, accepted, and effective
herapies are overlooked.
Bioenergy, “life energy,” is thought by some to influence
ind/body, mind/mind (person to person) and mind/mind
person to infinite spirit) relationships (336) and is altered
y conscious and unconscious efforts (336). Bioenergy is ielieved by some to affect psychological states and physio-
ogical processes of the nervous, endocrine, and immune
ystems (psychoneuroimmunology). It is likely that con-
ciousness manifested as thought, emotion, memories, fears,
nd self-concept can create physical changes in the body,
nd this appears modulated by many circulating mediators
uch as tumor necrosis factor (TNF)-alpha, which may
educe or eliminate a reward response in animals and may be
anifest by conditions such as MI. Blockers of TNF-alpha
etanercept) restore the reward response (337).
No sound scientific evidence demonstrates existence of
ioenergy fields. Scientific or not, bioenergy concepts are
eeply ingrained and has gained popularity. Out-of-hand
ismissal of influence of bioenergetics by a physician may
isrupt a relationship to a believing patient and cause the
atient to turn elsewhere.
The mind can influence health, life, and death (338,339).
nergy that facilitates connectedness, harmony, and health
an be as simple as emotional release in the form of mirthful
aughter or tears. Mirthful laughter can improve immune
ystem functioning (340). This form of bioenergy can be
arnessed to improve a patient’s well-being and outcome.
Belief in the benefit of treatment can improve outcome
ven if the treatment is a placebo. Controlled studies
howing benefit of bioenergy approaches over placebo raise
he issue of a potential mechanism of effect with functional
agnetic resonance imaging (MRI) that can show blood
ow changes during brain mapping.
Many cardiovascular symptoms are not treated easily with
resent medical therapy. Functional complaints, such as
hest pain, palpitations, dyspnea, fatigue, and weakness not
ssociated with measurable physical abnormalities are poorly
nderstood, and methods to eliminate consequences could
reatly improve health (286). Reinterpretation of the symp-
oms and their severity by the patient (mental energy) may
ave an influence on outcome. The real benefit of these
reatments might be as an adjunct to improve patient
ptimism and outcomes by their psychosocial effects (280).
A sense of peace, serenity, calm, power, or emotional
onnection can have potent influence on outcomes (286).
emoval of stress (not yet well defined) by a technique
tilizing bioenergy may modify severe disabling symptoms
ven if the therapy has no proven benefit. Such an approach
an be advocated as long as it does not exclude standard
herapy and does not cause harm.
ethods to Study Bioenergy
lthough bioenergy may be immeasurable, patients—and
herapists—will continue to use bioenergy approaches if
onvinced of their efficacy, no matter the resolve of a specific
cientific, or medical community to discount benefits even if
here is scientific demonstration of inefficacy. Adjusting
ioenergy fields through acupuncture, therapeutic touch, Qi
ong, Johrei, Reiki, crystal therapy, and magnet therapy maymprove health, but data are too preliminary to recommend
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f benefit and the mechanisms responsible are unknown.
Traditional Chinese medicine encompasses folk practices
ased on mysticism and bioenergy (342). A recent analysis
f 2,938 clinical trials reported in Chinese medical journals
hows these data to be inconclusive (343). Chinese trials
ere qualitative, short-term, small, poorly controlled, rarely
linded, and contained inadequate data.
orms of Bioenergetics
he techniques share common features: focus on “bioen-
rgy” by practitioners and “energy transfer” leads to benefi-
ial effects.
elaxation. Relaxation therapy in 192 men having two or
ore risk factors for CAD was associated with better
utcomes compared to a control group (344). “Type A”
ersons tending to have a higher incidence of hypertension
nd death from CVD may benefit from a relaxation re-
ponse (345–348). Progressive muscle relaxation techniques
ave been associated with improved cardiovascular out-
omes, but data are still preliminary.
oga. Movements and positions in yoga and the breathing
xercises can lower the blood pressure and alter breathing
atterns (349). Among other improvements in physical
tness, yoga can increase absolute and relative maximal
xygen uptake by 7% and 6%, respectively, after eight weeks
n a controlled setting (341). Yoga has been associated with
mproved heart rate variability and respiratory variables
350). There can be a decrease in sympathetic response
350,351) and changes in baroreflex sensitivity (352). Yoga
ay influence the progression and regression of atheroscle-
osis (353), and may beneficially alter the lipid profile (354),
ut the data are too preliminary to make a sound recom-
endation in favor of yoga.
i Gong. Qi Gong has increased dramatically. Qi means
ife-force energy and Gong is “practicing skill.” Practitioners
elieve that vital energy circulates through “meridians,”
onnecting all organs, and illness is an imbalance, or
nterruption, of Qi. Qi Gong is said to re-balance the energy
355).
Internal Qi Gong involving deep breathing, concentra-
ion, and relaxation is a self-discipline that trains body and
ind to alter flow of “vital energy.” In 76 post-MI patients,
i Gong was associated with improvement in respiratory
ate, heart rate, and respiratory sinus arrhythmia (356). In
imilar study, hospitalization was reduced in post-MI pa-
ients learning Qi Gong relaxation techniques (357). In
ypertensive patients, Qi Gong was associated with an
mprovement in levels of prostoglandin (357).
“External Qi Gong” is performed by “masters” who claim
o cure with energy from their fingertips. Control Qi is
laimed to diagnose and cure various conditions (357). Qi
ong may influence and reduce respiratory rate, heart rate,
lood pressure, and accentuate vagal tone demonstrated by
hanges in heart rate variability (358–360). However, th
linical significance and mechanisms are unclear (361). tOver 1,300 references on Qi Gong suggests benefit to
reat hypertension, respiratory diseases, and cancer. For
ypertension, lower stroke and mortality rates have been
hown in preliminary studies (362). Qi Gong may benefit
ome patients with atherosclerotic obstruction of the lower
xtremities (363), and breathing approaches might influence
ymptoms in patients with mitral valve prolapse (364).
eiki. Reiki is believed to use “healing energy” to enhance
itality, resiliency, and health for both practitioner and
atient (365,366). There are over 500,000 practitioners.
he technique’s most profound effect is deep relaxation. It
orks, supposedly, only if the receiver can detect the subtle,
ersonal, unconscious energy. A practitioner “attuned” to
he energy places his hands onto or just above the patient’s
ody at strategic points (chakras) to transfer energy. Chan-
eling this energy is purported to have a positive effect, but
cientifically demonstrable cardiovascular effects have not
een shown (367).
ealing and therapeutic touch. Healing touch (HT) and
herapeutic touch (TT) use the concept of energy fields
auras), energy centers (chakras), and energy tracts (medi-
ns) to empower healing similar to Reiki.
Healing touch, developed by Janet Mentgen, RN (368),
s used extensively by nurses (68,000 participants in the
.S.) at all levels of health care, but it based on little
upportive controlled data. Universal energy is believed to be
hanneled to work with human “energy fields” to restore
armony and balance. The technique utilizes the hands to
lear, energize and balance the human energy fields, thus
ffecting physical, emotional, mental, and spiritual health.
Healing TT is a therapeutic intervention, an educational
rogram, and an international organization that provides
ealing touch certification and formulates standards of
ractice (368).
In therapeutic touch, hands are used to direct healing
nergy. Healing supposedly results from transfer of “excess
nergy” from healer to patient. Therapeutic touch was
onceived in the 1970s by Dolores Krieger (369). Thera-
eutic touch involves “centering” (align the healer to the
atient’s energy level), “assessment” (hands detect forces
rom the patient), “unruffling the field” (sweeping stagnant
nergy downward to prepare for energy transfer), and energy
ransfer (from practitioner to patient) (370).
Therapeutic touch was evaluated in a meta-analysis by
stin et al. (371). Of the 11 trials reviewed, 7 showed a
ositive treatment effect and at least one outcome. These
ncluded a 17% decrease in anxiety in cardiac care unit
CCU) patients, reduced need for postoperative pain med-
cation, and improved wound healing.
Healing TT may reduce anxiety but no sound scientific
vidence supports the postulated “energy transfer” benefits
laimed. Benefits reported may simply be a placebo effect,
iterally a “laying on of hands” (372).
istance healing. Similar to TT and distance (interces-
ory) prayer, “distance healing” is energy transfer that is said
o occur over very long distances. Beutler et al. (373) showed
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July 5, 2005:184–221 ACCF Complementary Medicine Expert Consensus Documentmall but significant changes in diastolic blood pressure in a
ouble-blind controlled study of distance healing. One
tudy showed benefit of distance (blinded) prayer on auto-
omic tone based on skin conductance levels and “blood
olume pulse” (373,374).
pplied kinesiology. This technique of kinesiology is per-
ormed by therapists using acupressure points and a muscle-
esting method to diagnose nutritional and glandular “defi-
iencies,“ which are then “corrected“ by manipulation or
utrition supplements. There is little substantiated support-
ve data.
editation. Meditation, not universally considered bioen-
rgy therapy, can alter blood distribution in the brain
bserved by magnetic resonance imaging scans and can
ncrease delta wave activity observed on the electroenceph-
logram. Rage behavior decreases. Transcendental medita-
ion has been linked to reduction in cardiovascular mortality
375–382). It can lower blood pressure (383–385). Zen
editation has been associated with improved heart rate
ariability and slowing of respiratory rate (384). These data
re preliminary and techniques cannot be recommended yet.
ibrational medicine. Practitioners of vibrational medi-
ine consider humans as dynamic energy systems (“body/
ind/spirit” complexes). People are influenced by subtle
motional, spiritual, nutritional, and environmental energies
hat affect health (386). These concepts involve vibrational
edicine: aromatherapy, chakra rebalancing, distance heal-
ng; flower essence therapy, homeopathy; Kirlian photogra-
hy, moxibustion, orthomolecular medicine; past-life re-
ression, radionics; and other unfounded approaches.
agnetotherapy. “Magnetotherapy” is applied through
he use of permanent or fluctuant magnetic fields, but there
re no proven benefits for the CVD (387,388). Scherlag has
een evaluating, in an animal model, low-level gauss fields
o affect atrial arrhythmias in preliminary studies (389).
omeopathy. Water is believed to retain the memory of
nd be energized by compounds that existed in it. Scanning
f water by MRI suggests there might be some, but no data
as demonstrated health benefits for CVD (390). A meta-
nalysis of homeopathic treatments in the Lancet of more
han 80 studies indicated, compared to placebo, that ho-
eopathic treatments might be effective (391,392). Al-
hough the results were significant as a whole, concerning
ny one-disease entity, no significant treatment could be
iscerned. The therapies were not standardized.
aveats
otential beneficial effects of these approaches may be in
art due to an undefined psychological impact that might
ltimately create a physiological effect. The approaches have
ot been tested for safety. There are no specific proven
ardiovascular benefits from any of these therapies to treat
isease.
Potential adverse influences may be the release of inhibi-
ions causing anger, hostility, “negative” energy, or reduc-
ion of needed sympathetic tone. No bioenergy therapy haseen shown to alter the natural course of CVD (392). These
herapeutic approaches may appear to have benefit as an
djunct to standard medical therapies and for patients with
evere functional, yet symptomatic, complaints, but actual
enefits are difficult to measure. Bioenergy approaches
hould not be considered substitutes for standard medical
are; they may offer false hope to patients and at an
xpensive price.
Practitioners and patients who use these techniques will
ikely continue to employ them even without a scientific
oundation. Practitioner qualifications are difficult to mea-
ure (393).
“Benefits” may represent the natural course of a disease or
he patient’s or therapist’s interpretation of the condition.
ositive results may represent experimenter biases not ob-
ious from the study design. Patients may undergo “energy
ealing” and be cured of a condition that they do not have
r they may be misdiagnosed. A bioenergy practitioner
ight exaggerate or create an illusion of the benefit of
herapy. Biases for, and against, bioenergy healing make it
ven more difficult to assess the quality of the data.
Ongoing studies including those funded by the NCCAM
re evaluating energy healing approaches.
ecommendations
onditions for which bioenergy therapies are not contrain-
icated (but not specifically recommended) include:
. If a bioenergy treatment does not interfere with stan-
dard, accepted, and proven therapy.
. If standard therapies do not provide optimal symptom-
atic improvement, or for a condition that is potentially
functional or has functional overlay.
No bioenergy therapy should be considered a substitute
or standard, accepted, and approved therapies. If any
ioenergy approach is considered, one should choose a
ractitioner who has a good reputation, appears to have
ood results, and is willing to work with medical profes-
ionals.
. SPIRITUALITY/INTENTIONALITY
pirituality in Cardiovascular Applications
nectdotally the will to live, a strong life force spirit or faith,
loving family or community, or the absence of these
eatures has been considered related to outcomes in cardio-
ascular care. Synchrony between belief systems or other
connections” between patient and healer are also widely
onsidered important on an intuitive basis.
Some indigenous master healers from various cultures
nd faiths assert that medicines and procedures constitute
nly about 20% of what heals and that 80% is mediated
hrough the spirit (394,395). With remarkable uniformity
cross these healers, the “spirit” is considered an integral
lement of optimal diagnosis and therapy (396,397).The ramifications of such claims, if even partly true, are
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f such claims based on available data. The ubiquitous
resence of spiritual beliefs and practices present since
ncient times mandates systematic examination (339,398–
07).
Intuitively, the role of spirituality in modern cardiovas-
ular care offers both the potential to better understand and
upport patients who face cardiac death and provide new
uestions for therapeutic interventions. Thousands of ob-
ervational, instructional, anecdotal, theological, and philo-
ophical treatises suggest the potential impact of the spirit in
ealth, including passages from the Bible, the Koran, the
panishads, the transcribed teachings of Buddha and other
eligious literature.
ompendia
number of well-referenced overviews or comprehensive
ompendia of references have been compiled on scientific
nvestigations into spiritual and religious practices correlated
ith cellular, physiologic, somatic and psychosomatic heal-
ng applications. These books and compendia can be found
n the ACCF Web site as Appendix VI and include
eferences using broad arrays of study designs with a
eterogeneous nomenclature and definitions specific to the
eart. Two consistent themes include epidemiologic obser-
ations that both personal and social spirituality have
orrelations with selected outcomes measures, and that
pirituality, particularly prayer, may have efficacy in healing
pplications. Data quality, selection bias, interpretative bias,
ublication bias, and details of safety issues are not discern-
ble from these compendia.
eview Articles and Meta-Analyses
arious structured reviews and meta-analyses of spiritual
escriptors and therapies and their correlations with clinical
utcomes (not specific to cardiology) have also emerged in
he peer review literature and can be found on the ACCF
eb site as Appendix VII. This literature overall is well
ummarized in the Astin et al. (371) recent meta-analysis of
linical studies involving spirituality. The researchers ac-
nowledge that available reports were so heterogeneous in
tructure, methods, population, and end points measured
hat their attempt to perform a classical meta-analysis had to
e “abandoned.” The present writing group’s consensus
verview of these reviews suggest:
. The literature in this area is devoid of mechanistic
insight and is heterogeneous as to the quality of study
design.
. There is no scientific evidence in the literature
sufficiently definitive or compelling to provide a basis
for specific recommendations on the use of spiritual
intervention for healing purposes in a cardiology
population. m. There is a notable consistency across reports suggesting
efficacy.
. There are no obvious safety issues attendant to spiritual
interventions.
pecific Reports of Spirituality and Cardiovascular Care
pidemiologic evidence correlating individual spiritual
ractice, involvement within a spiritual community, and of
ommunities characterized by their spiritual practices with
mproved cholesterol levels, more normative blood pressure,
ther risk factor modulations, incidence of clinically recog-
ized coronary disease, incidence of MI, post-coronary
rtery bypass graft (CABG) survival, and improved survival
verall provides an intriguing context for other observations
f psychosocial descriptors—including personality type,
ostility, depression, isolation, and cardiac outcomes (408–
18). As with all epidemiologic data, however, it remains
nclear whether or not there is actually a causal relationship
etween these spiritual features and the clinical outcomes.
Reports of palliation of subjectively perceived stress
nd/or pain levels in patients admitted to the CCU or
ndergoing cardiac catheterization constitute another area
ntriguing both for its consistency and for its apparent
verlap with the use of imagery, relaxation, and other
iofield and energy healing techniques in similar patients
419–421). Only one preliminary report, however, has
ctually correlated such palliative end points with clinical
utcomes (394–397,422).
Four prospective, randomized, double-blinded clinical
rials examining the influence of off-site prayer on clinical
utcomes in cardiac patients have been reported (394,395).
n three of the studies, CCU patients were assigned either
o off-site intercessory prayer or no prayer in addition to
tandard care. In two of the CCU studies, a combined index
f hospital course and complications severity was derived
pecifically for study purposes (397). Although findings
ere reported as significantly improved in each cohort
reated with off-site prayer, clinical interpretation of these
ndings is difficult. In the third CCU study (396), no
ignificant differences existed in clinical outcomes, although
he study was powered to a higher treatment effect than may
ave been observed. The fourth study was a feasibility pilot
xamining an array of CAM practices in patients with acute
oronary syndromes undergoing invasive catheterization
nd angioplasty (396). Using major adverse cardiac events
MACE) and blindly analyzed continuous electrocardio-
raphic evidence of post-angioplasty ischemia, absolute
eductions were observed in the prayer group relative to the
tandard therapy group; however, these difference did not
each statistical significance (423). Two additional prospec-
ive, multicenter clinical studies of double blind off-site
rayer in patients undergoing CABG and percutaneous
oronary intervention, respectively, have completed enroll-
ent and will soon be reported (422).
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upport versus spiritual therapy. Careful consideration
ust be given to the important differences between render-
ng spiritual support for patients and families and the study
f experimental, directed spiritual therapy.
Spiritual support constitutes the response of the health
are system to the self-perceived spiritual needs of the
atient and family. Access to a chapel, the presence of a
haplain, awareness of and sensitivity to spiritual and ethnic
references—spiritual support services can broadly be seen
s the health care system’s readiness and sensitivity to needs
dentified by patient and family, particularly in the face of
ife-threatening illness. Spiritual support might be a com-
onent of therapy focused on recovery from illness, or it may
e involved as tools for coping, for grief, or for transcendence
f impending death. It is generally appropriate for spiritual
upport services to be assessed and advanced through a quality
ssurance/quality improvement (QA/QI) process. External
gencies appropriate for overview of QA/QI include the
oint Commission for Hospital Accreditation.
Spiritual therapy implies a healing objective actively
ought and documented through experimental intervention.
ormal research protocols, Institutional Review Board pro-
esses, and informed consent from patients are appropriate.
pecific considerations of methodology, mechanism, dose
nd dose response, and other aspects fundamental to work
ith any new therapeutic agent in cardiology patients are all
pplicable. Peer-review grant funding for spiritual therapy
rotocols is currently identifiable at the NCCAM and other
gencies at the NIH. New standards and recommendations
or study in this area have recently been published (424–
29).
pirituality and religion. “Religion,” the “religious,” and
he “spiritual” are terms used synonymously to refer to that
hich connects the mortal being to the highest sense of
eaning and order at a transpersonal level. In other usage,
he term “religion” implies established ethnic and cultural
roups, and in some cases evokes the concept of a divinity,
hereas “spiritual” implies a more generic attribute.
nique baseline spirituality patient descriptors. Epide-
iologic evidence is compelling that baseline spirituality
escriptors characterized by established questionnaires are
ssociated with certain cardiac outcomes (417). In one
eport, the degree of the spirituality effect was equivalent to
history of cigarette smoking (430). Further study and
specially prospective multivariate models will be important
o better understand the predictive information content of
aseline spirituality in conjunction with other classical
ardiac predictors of outcome (e.g., age, ejection fraction,
ender).
ethods and spiritual therapy. No discrete measurements
eport intensity or “dose” of spiritual therapies. Qualitative
eatures include descriptions of the practice itself, the
ontent of the prayer, meditation, intention or imagery
sed, the experience level of the practitioner, any notable athnic affiliations, and/or the use of ancillary components
uch as music, soft abdominal breathing, humming or
hanting, a prescribed body posture or the like. Quantitative
eatures, such as the number of individuals praying, the
uration of the prayers, and the proximity to the patient, are
lso of potential interest.
echanism of action and surrogate measures. “Divine
ntervention,” “life force,” “love,” “joy,” and “spirit” all share
common feature—the absence of any satisfactory mecha-
istic explanation as to how they operate in health or
isease. Three explanations are widely discussed:
. These forces are divine, and so cannot be compre-
hended, particularly within a deterministic model.
. These forces cannot be measured because they do not
exist.
. These forces are self-evident, and we simply have not
yet developed measurement tools.
In the absence of discrete measurements or appreciable
echanisms of action, and in the presence of spiritual
ractice imbued in the culture of patients, families, com-
unities, and health care staff, a pure control group for
pirituality trials is difficult, if not impossible, to develop.
hus, studies in this area can currently examine incremen-
al, but not absolute, therapeutic effects.
afety and efficacy end points in spiritual therapy studies.
election of efficacy end points for study in this area must be
onsistent with the population studies. For patients with
ery advanced heart disease, where end of life issues may
ecome ascendant over mortality per se, the influence of
piritual interventions on end of life measures would be a
easonable approach.
Conversely, if spiritual therapy shows a therapeutic effect
t may be capable of causing harm. As with any new therapy
hose mechanism is undefined, it is unreasonable to simply
ssume safety and study efficacy—addressing safety, with
ata Safety Monitoring Boards, should be formally in-
luded in trials as a safety and efficacy study design.
Similarly, as research with potential safety issues atten-
ant, clinical trials applying spiritual intervention to cardi-
logy patients as an investigational therapy should do so
ith the informed consent of the patient.
ensitivity, privacy, and ethics. Spiritual matters consti-
ute one of the most private and personal areas for both
atients and staff. Sensitivity to the broad array of belief
ystems and to the highly symbolic nature of certain terms,
oncepts, or icons is paramount to develop spiritual support
ystems and studies of spiritual therapy. Incorporation of
piritual assessments as part of standard nursing admission
rocedures or the acquisition of spirituality survey informa-
ion in conjunction with research protocols must be con-
ucted with strict attention to whether the patient finds the
ueries objectionable and to the confidentiality of the
aterial and with informed consent.
Cultural preconceptions and bias regarding spiritualityre substantial, with some issues that are primarily philo-
s
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ikely to be contentious when discussed broadly. Crucial
ssues include:
How do we know when God answers prayer?
Does one religion have more powerful prayer?
How would a negative study of prayer be interpreted?
Is death a negative end point?
Is technology necessary in the setting of true faith?
It seems reasonable to examine spiritual therapy as an
djunct to modern technology, not as competition or a
eplacement for standard care. It is reasonable to assess the
afety and efficacy of spiritual interventions with reasonable
ut rigorous science and clinical trial designs. It is reason-
ble to investigate physiologic signals that might provide
ither a marker of the presence of spiritual influence or even
key to mechanisms through which spiritual influence is
ediated.
Extension of dialogue across the disciplines and constit-
encies concerned with spiritual support and spiritual ther-
py is timely and important.
elivery Roles, Accreditation, and Certification Standards
ptimal spiritual support or therapy requires considerable
e-thinking regarding the relative roles of the patient, the
amily, the community, the clergy, and hospital staff. As
on Carlos Peete stated in his 1955 book The Psychosomatic
enesis of Coronary Artery Disease: “I believe the most
uccessful physician will instill into his patient hope, cour-
ge, and patience. He can do so only if he has these virtues
imself. The discipline necessary to face the responsibilities
hat are ours as individuals and as a people can be attained
nly when we understand and use both the spiritual and
hysical laws in our daily lives” (311,323,324).
ummary and General Recommendations
piritual needs, influences, and therapeutic claims are an-
ient and ubiquitous. Spirituality issues are pertinent to
atients with heart disease. Recommendations include:
. Development of health care responsive to the spiritual
needs of patients and families.
. No practice guidelines for spiritually based therapy in
cardiovascular care can be currently recommended.
. Clinical research of spiritual interventions in cardiology
settings is reasonable, should be conducted as safety and
efficacy trials, and ethically must include the informed
consent of patients.
. The use of unique baseline descriptors of spirituality in
clinical trials is suggested.
. Development of a common nomenclature, use of stan-
dardized measures, and detailed methodological de-
scriptions in clinical trials of spiritual interventions are
recommended.The cultivation of multidisciplinary forums on concepts Af spirituality and healing, delivery roles, practice standards,
nd certification issues is suggested.
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PPENDIX I: RELATIONSHIPS WITH INDUSTRY
riting committee members were asked to identify all
elationships with industry that were relevant—or could be
erceived as relevant—to this document. One member, Dr.
enneth Pelletier, declared that he had past (not current)
esearch grants with Medtronic and Merck. The other
uthors of this document declared that they had no relevant
elationships with industry pertinent to this topic.
PPENDIX II: GLOSSARY
cupressure. Acupressure is an ancient Asian healing art
hat uses the fingers to press key points on the surface of the
kin. Practitioners believe this stimulates the body’s immune
ystem to self heal. When stimulated, these points may
elieve muscular tension and promote the release of endor-
hins—neurochemicals that relieve pain. Acupressure uses
he same points and meridians (patterns of energy flow) as
cupuncture, but instead of needles it treats with gentle,
rm pressure of fingers and hands.
cupuncture. Acupuncture is a treatment based on an
ncient Chinese medicine. Acupuncture places extremely
hin, sharp needles (that are sometimes connected to a
ow-voltage power source) along a network of “lines of
nergy” or meridians on the body surface. Chinese medicine
ractitioners believe these meridians conduct energy
hroughout the body. However, recent (Western) evidence
ndicates that the needles stimulate sensory nerves underly-
ng meridians to alter neurotransmitter release in regions of
he central nervous system concerned with regulation of the
utonomic nervous system and hence the heart and blood
essels. Acupuncture is believed by clinicians practicing
raditional Chinese medicine (TCM) to balance the oppos-
ng forces of yin and yang, keep the normal flow of energy
nblocked, and maintain or restore health to the body and
ind (http://nccam.nih.gov/health/acupuncture/#glossary,
ccessed September 18, 2002). Eastern scientists have trans-
ated these TCM concepts into a neurophysiologic para-
igm in which acupuncture, by evoking the release of
nhibitory neurotransmitters (endorphins, enkephalins, and
ossibly endomorphins) in the hypothalamus, midbrain,
nd medulla, in turn, reduces activity of premotor neurons
oncerned with sympathetic outflow to the heart and
ascular system (1).
HA dietary guidelines. October 2000 revision of the
HA dietary guidelines to Americans (1).
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ormed by therapists, using acupressure points and a
uscle-testing method. Practitioners believe they are able to
iagnose nutritional and glandular “deficiencies” that are
hen “corrected” by manipulation or nutrition supplements.
tkins diet. Developed by Dr. Robert Atkins, this diet
imits carbohydrates to 20 g initially for rapid weight loss.
his is done by eliminating high carbohydrate foods such as
read, potatoes, pasta, fruit, juices, and candy. Fats and
roteins are the main source of fuel on this diet. Meat, eggs,
utter, and most cheeses can be eaten without restriction.
ioenergy (bioenergetics). Bioenergetics is a loosely col-
ected series of healing “disciplines” that attempt to harness
atural forces and powers to influence natural healing
rocesses. Bioenergy fields are thought to be altered by
onscious and unconscious efforts (330). Bioenergy medi-
ine uses bioenergy (HT and TT, Qi Gong, Johrei, Reiki,
rystal therapy, relaxation therapy, distance healing, applied
inesiology, and magnet therapy) to heal (431).
iofeedback. Biofeedback (BF) techniques are treatment
ethods that use monitoring instruments of various degrees
f sophistication. The BF techniques provide patients with
hysiologic information that allows them to reliably influ-
nce psychophysiological responses of two kinds: 1) re-
ponses not ordinarily under voluntary control, and 2)
esponses that ordinarily are easily regulated, but for which
egulation has broken down. Technologies that are com-
only used include electromyography (EMG BF), electro-
ncephalography, thermometers (thermal BF), and galva-
ometry (electrodermal BF) (432).
rystal therapy. Practitioners believe that crystals contain
r possess energy fields that can be used to heal. Practitio-
ers believe that each crystal is associated with different
nergy fields or emotions.
istance healing. There is much overlap among TT,
istance healing, and distance prayer. Spiritual healing
racticed when the patient is not present is called distance
ealing and is similar to prayer. It can be practiced in groups
r individually.
uided imagery. A patient is asked to focus deliberately on
particular image in order to “relax, manage stress, or
lleviate a specific symptom” (433). Key to this therapy is
hat the patient is in control of the image and can redirect
t. The image does not have to be physiologically true, as in
he case of a cancer patient imagining being free of cancer,
r even real in the sense that the patient has or would ever
xperience what the image depicts. Imagery may be just
imple visualization or a sensory perception such as a smell,
touch, or a sound (325,434,435). Although imagery uses
he conscious mind, it may also be utilized to tap into the
nconscious or less conscious mind.
o’oponopono. This Hawaiian approach alleges to find
he divine within oneself to remove stress and release
roblems. It involves repentance and “transmutation” to
rovide spiritual freedom, love, peace, and wisdom (431). mydrotherapy. The concept behind this technique is that
ater is “energized” by compounds in extremely dilute
mounts. Practitioners believe that water retains the mem-
ry of the compounds that existed in it. This may reflect
ilute amounts of the retained original compound.
ypnosis. Hypnotic techniques induce states of selective
ttentional focusing or diffusion combined with enhanced
magery. They are often used to induce relaxation and also
ay be a part of cognitive behavioral therapy. The tech-
iques have both pre- and post-suggestion components.
he pre-suggestion component involves attentional focus-
ng through the use of imagery, distraction, or relaxation,
nd has features that are similar to other relaxation tech-
iques. Subjects focus on relaxation and passively disregard
ntrusive thoughts. The suggestion phase is characterized by
ntroduction of specific goals; for example, analgesia may be
pecifically suggested. The post-suggestion component in-
olves continued use of the new behavior following termi-
ation of hypnosis (431).
agnetotherapy. This therapy is applied through the use
f permanent or fluctuant magnetic fields.
editation. Meditation is a self-directed practice for re-
axing the body and calming the mind. Various meditation
echniques are in common use; each has its own proponents.
editation generally does not involve suggestion, autosug-
estion, or trance (436,437).
editerranean diet. This is a diet high in fruits, vegeta-
les, bread and other cereals, potatoes, beans, nuts, and
eeds. Olive oil is an integral part of the diet and is an
mportant source of monounsaturated fat. Dairy products,
sh, and poultry are eaten in low to moderate amounts and
ittle red meat is consumed. Up to four eggs are consumed
eekly and wine is drunk with meals in low to moderate
mounts.
ental physics. This is purported to be a practical, holis-
ic, futuristic science that manifests “hidden meaning” of the
ible and involves “astral travel;” aura reading chanting;
editation, pranayama (“deep scientific breathing exer-
ises”); “pranic therapy” (a variant of channeling); reflexol-
gy; shiatsu; and individualization of diet according to
chemical type” (438).
ind/body. Mainstream mind-body medicine, as defined
y Chiarmonte (438a), is “based on the premise that mental
r emotional processes (the mind) can affect physiologic
unction (the body).” Lazar (438b) elaborates on this point
urther, saying that mind-body medicine is an integrative
iscipline that examines the relationship between psycho-
ogical states and psychological interventions and between
hysiology and pathophysiological processes. Conversely,
ost practitioners of CAM—which takes a different ap-
roach to mind/body medicine—hold that the mind’s
mpact on the body is not unidirectional; rather, there is an
ntegrated process in which both mind and body affect each
ther (439).
usic therapy. Music therapy is the prescribed use of
usic by a qualified person to effect positive changes in the
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ndividuals with health or educational problems (440).
utrition. This concerns cardioprotective diets, including
HA Step I and Step II; Mediterranean; NCEP ATP III;
ASH, low-fat and low-sugar diets. Also includes garlic,
uts, teas, and alcohol use.
lacebo. A placebo is defined as an inert or innocuous
reatment that works not because of the therapy itself but
ecause of its suggestive effect. It is considered a mind/body
odality, but with some distinct differences. Placebo ther-
py depends on the power of a patient’s belief that the
herapy will be effective (431).
ranic psychotherapy. Pranic psychotherapy includes re-
oval and disintegration of “traumatic psychic energy,”
isintegration of “negative elementals” (“bad spirits”), and
reation of a “positive thought entity.”
rogressive muscle relaxation (PMR). Progressive muscle
elaxation focuses on reducing muscle tone in major muscle
roups. Each of 15 major muscle groups is tensed and then
elaxed in sequence.
i Gong. Qi is life force energy and Gong is “practicing
kill.” Practitioners of Qi Gong believe that vital energy
irculates through “meridians,” connecting all organs. Illness
s attributed to an imbalance, or interruption, of Qi. Qi Gong
s said to re-balance “yin” and “yang” (365).
nternal Qi Gong. Involves deep breathing, concentration,
and relaxation. It is a self-discipline that trains body and
mind to alter flow of “vital energy,” for self-reliance and
adjustment, to cure disease, and to strengthen and
prolong life.
xternal Qi Gong. Affects things outside one’s body. It is
performed by “masters” who claim to cure with energy
released from their fingertips.
eiki. Rei is “universal,” or “spiritual,” and Ki is “life force
nergy.” It is a form of laying on the hands (431).
elaxation. Relaxation techniques are a group of behav-
oral therapeutic approaches that differ widely in their
hilosophical bases as well as in their methodologies and
echniques. Their primary objective is the achievement of
ondirected relaxation, rather than direct achievement of a
pecific therapeutic goal. They all share two basic compo-
ents: 1) repetitive focus on a word, sound, prayer, phrase,
ody sensation, or muscular activity, and 2) adoption of a
assive attitude toward intruding thoughts and a return to
he focus. These techniques induce a common set of
hysiologic changes that result in decreased metabolic
ctivity. Relaxation techniques may also be used in stress
anagement (as self-regulatory techniques) and have been
ivided into deep and brief methods (441).
eversal diet. The Ornish reversal diet consists of 10% fat
nd is combined with a program of smoking cessation,
erobic exercise, stress management training and psycholog-
cal support.
pirituality. Spirituality can be defined as a belief systemocusing on intangible elements that impact vitality andeaning to life’s events (431). In the absence of insight into
he mechanism, the entire area of spirituality and cardio-
ascular health remains highly anecdotal, intuitive and
peculative. As patients and families of loved ones who have
eart disease face mortality in a very personal and immedi-
te way, however, there is widespread interest in how
ardiologists think about and approach spiritual issues in
ractice and in research.
upplements. The Dietary Supplement Health and Edu-
ation Act (DSHEA) of 1994 defined dietary supplements
s a product (other than tobacco) intended to supplement
he diet that bears or contains one or more of the following
ngredients: vitamins, minerals, herbs, or other botanicals,
mino acids, and substances such as enzymes, organ tissues,
landulars, and metabolites. Whatever their form, DSHEA
laces dietary supplements in a special category under the
eneral umbrella of “foods,” not drugs, and requires that
very supplement be labeled a dietary supplement (http://
ww.cfsan.fda.gov/dms/ds-oview.html, accessed Septem-
er 18, 2002). Other examples include antioxidants, plant
terols, soluble fiber, omega-3 fatty acids and soy; herbs,
uch as Ginkgo biloba, guggulipid, and HCSE; and other
upplements, such as, L-arginine, L-carnitine, and CoQ10.
herapeutic touch. Practitioners believe that their hands
re used to direct healing energy. Healing supposedly results
rom transfer of “excess energy” from healer to patient.
ranscendental meditation. Transcendental meditation
ocuses on a “suitable” sound or thought (the mantra)
ithout attempting to actually concentrate on the sound or
hought.
ibrational medicine. Considers humans as dynamic en-
rgy systems (“body/mind/spirit” complexes). The dynamic
nergy system, the life force, is influenced by subtle emo-
ional, spiritual, nutritional, and environmental energies.
ealth and illness originate in “subtle energy systems.”
oga. Developed in India, yoga is a psycho-physical discipline
ith roots dating back about 5,000 years. Today, most yoga
ractices in the West focus on the physical postures, termed
asanas,” breathing exercises called “pranayama,” and medita-
ion (source: http://www.yogasite.com/yogafaq.html#What).
en meditation. This technique is a form of Buddhism
riginating in Asia; it teaches that desires are the primary
ause of suffering. Meditative absorption in which all
ualistic distinctions are eliminated (source: http://
ealing.about.com/cs/zen/index.htm?termszen
editation) (236).
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